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Lakshmi Milind Prabhu 
TARGETING PROTEIN ARGININE METHYLTRANSFERASE 5 AS A NOVEL 
THERAPEUTIC APPROACH IN PANCREATIC & COLORECTAL CANCER 
Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) 
are among the most commonly diagnosed forms of cancer in the United States. 
Due to their widespread prevalence and high mortality rate, it is vital to develop 
effective therapeutic drugs to combat these deadly diseases. In both PDAC and 
CRC, the multifunctional factor nuclear factor kappa B (NF-kB), a central 
coordinator of cellular immune responses, is activated abnormally, leading to 
tumorigenesis and cancer progression. Therefore, controlling NF-kB activity is 
critical in the treatment of these cancers. In a previous study, we identified a new 
mechanism by which NF-kB activity is regulated by an epigenetic enzyme known 
as protein arginine methyltransferase 5 (PRMT5). We showed that 
overexpression of PRMT5 not only activated NF-kB, but also significantly 
promoted several characteristics associated with cancer, including increased cell 
proliferation, migration, and anchorage-independent growth in both PDAC and 
CRC cells. Moreover, in order to examine the therapeutic potential of PRMT5 in 
these cancers, we adapted the state-of-the-art AlphaLISA technique into a high 
throughput screen (HTS) platform to screen for PRMT5 inhibitors. As a result, we 
successfully identified the small molecule PR5-LL-CM01 as our lead hit. Further 
validation experiments confirmed that PR5-LL-CM01 is a potent and specific 
PRMT5 inhibitor that exhibits significant anti-tumor efficacy in both in vitro and in 
vivo models of PDAC and CRC. Additionally, in a second screen, we discovered 
x 
two natural compounds, P1608K04 and P1618J22, that can also function as the 
PRMT5 inhibitors. These findings further highlight the robustness of the PRMT5-
specific AlphaLISA HTS technique. To conclude, we describe here for the first 
time a novel role of PRMT5 as a tumor-promoting factor in PDAC and CRC 
through NF-kB activation. By successfully developing and applying an innovative 
AlphaLISA HTS technique, we discovered PR5-LL-CM01, P1608K04, and 
P1618J22 as novel PRMT5 inhibitors, with PR5-LL-CM01 showing the strongest 
potency in both PDAC and CRC models. Therefore, we demonstrated that 
PRMT5 is a promising therapeutic target in PDAC and CRC, and the novel 
PRMT5 inhibitor PR5-LL-CM01 could serve as a promising basis for new drug 
development in PDAC and CRC. 
Tao Lu, Ph.D., Chair 
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CHAPTER 1. INTRODUCTION 
1.1 Pancreatic and Colorectal Cancer 
1.1.1 Risk factors, Genetic Causes and Stages  
Gastrointestinal cancer refers to malignant conditions of the 
gastrointestinal tract (GI tract) and accessory organs of digestion. Among them, 
pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are two 
of the most challenging cancer types (Siegel et al., 2013). For instance, PDAC 
has a very poor prognosis with a median survival between 6-8 months and ~8% 
of 5-year survival rate (Hidalgo 2010). Equally devastating, CRC is the second 
leading cause of death in men and women combined in the United States and 
the lifetime risk of developing this disease for both the sexes is 6% (Hawk and 
Levin 2005; Ferlay et al., 2015). Despite important advances in recent years, 
more than 40% of CRC patients will experience disease recurrence following 
primary therapy. Additionally, PDAC and CRC have different risk factors and 
genetic causes. The following sections elaborate on these topics in more detail: 
 
1.1.1A Pancreatic Cancer 
Several factors have been linked to an increased risk of developing 
pancreatic cancer. Some of these factors are lifestyle related, including obesity, 
tobacco use, and exposure to certain chemicals. However, other factors like age 
(most patients are older than 45 years), race (African-Americans have a higher 
incidence rates than Caucasians), family history of pancreatic cancer and 
personal history of chronic pancreatitis can also increase the risk of this cancer.  
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There are two broad categories of pancreatic cancer based on the cell 
type that the tumor originates from: exocrine and endocrine. Exocrine tumors are 
the most common type and arise mostly from the pancreatic ducts and are 
termed as PDAC. On the other hand, endocrine tumors account for only about 
1% of the pancreatic cancer cases and originate in the islet cells of the pancreas. 
According to the American Cancer Society, PDACs represent the majority of the 
pancreatic cancer cases. PDAC progression is characterized by the generation 
of precancerous lesions termed as low-grade pancreatic intra-epithelial neoplasia 
(PanIN) (Figure 1). It is now widely accepted that mutation in an oncogene 
termed Kras is the initiating genetic modification that occurs in pancreatic cancer 
and is seen in almost all PDAC specimens (Kern S, 2000, Hingorani et al., 2003, 
Hezel et al., 2006). Kras mediates a variety of functions like cell proliferation, 
survival and differentiation in normal cells. Point mutation in Kras (KrasG12D) 
causes constitutive activation of the gene and leads to development of PanINs in 
mice, which eventually progresses to PDAC formation. This particular mutated 
Kras form has been difficult to target via drugs, as directly targeting it has been 
an issue. This is because Kras lacks binding pockets for drugs to bind except for 
the site that binds to GDP/GTP. Since GDP/GTP show exceptionally tight binding 
to Kras, employing competitive nucleotide analogs with therapeutic effects has 
not been successful (Ye and Zhou, 2016). Apart from Kras, mutations in other 
genes have also been shown to accelerate PDAC formation. These include  
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Figure 1. Stages in Pancreatic Ductal Adenocarcinoma (PDAC) 
Development 
Accumulation of oncogenic mutations leads to conversion of normal acinar 
cells of the pancreas into a more ductal-like phenotype called acinar-to-ductal 
metaplasia (ADM). ADM lesions can progress into pancreatic intraepithelial 
neoplasia -1 and 2 (PanIN-1/2). In this stage, the cells change their 
morphology to a more cuboidal form. The nuclei remain in their basal position 
as seen in normal cells. PanIN-3 stage is characterized by loss of cell polarity 
and atypical nuclei with initiation of invasion of the basement membrane. 
PanIN-3 progressively leads to PDAC. This stage is characterized by with 
uncontrolled cell growth and metastasis. Cellular mutations that play a critical 
role for progression in each stage are highlighted in red and described in more 





mutation in the gene p16 that accelerates the PanIN 1/2 stages to the PanIN-3 
stage, which is designated as a carcinoma in situ. p16 regulates cell cycle 
progression from G1->S phase, and a loss-of-function can therefore lead to 
unchecked cell growth. Additional loss-of-function mutations in critical tumor 
suppressor genes like p53 and C. elegans gene Sma (S) and the Drosophila 
gene 'mothers against decapentaplegic' (Mad) (Smad4 (Horii et al, 1992) 
eventually lead G1->S- progression and evasion of apoptosis thereby completing 
the progression to PDAC. Clearly, pancreatic cancer formation is a result of a 
variety of mutations that can affect several downstream signaling pathways, 
resulting in a complex disease etiology.  
 
1.1.1B CRC 
CRC has become one of the more prominent cancers in developed 
countries spurred by a combination of factors including rising older population, 
unfavorable diet, smoking, low physical activity and obesity, that lead to an 
accumulation of somatic mutations (Slattery 2000). The risk of colorectal cancer 
is also increased in patients suffering from ulcerative colitis (Lakatos and Lakatos 
2008).  
 
CRC is comprised of a series of genetic and epigenetic changes in colon 
epithelial cells, with successive mutations that accumulate over time (Daniluk et 
al., 2012). This cancer originates in the colon and/or rectum at the inner lining in 
the form of an abnormal growth of tissue called a “polyp”. Polyps are benign in 
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nature and have not spread to surrounding tissue in the early stages and over 
time can undergo malignant transformation to give rise to metastatic forms of 
CRC. In later stages such as the late adenoma and metastatic stages, the cancer 
cells begin to invade the walls of the colon and rectum. The late adenoma stage 
thus leads to metastasis marked by with uncontrolled cell growth and spreading 
to neighboring and distant tissue and lymph nodes (Figure 2). There are several 
pathways that lead to chromosomal instabilities in CRC. These mutations result 
in activation of oncogenes such as Kras and inactivation of tumor suppressor 
genes such as the loss of APC, p53, and heterozygosity for the long arm of 
chromosome 18 (18q LOH) (Mundade et al., 2014) and lead to uncontrolled cell 
growth, escape from pro-apoptotic signals and eventually ability to metastasize 
as the cancer progresses from the early to the more advanced stages of CRC.  
 
1.1.2 Current Treatment Options and Limitations 
The available options for treatment are hardly adequate in improving the 
quality of life of PDAC and CRC patients. For PDAC, current therapy mainly 
consists of surgery, if diagnosed in the early stages. In more advanced stages, 
combined local treatment of radiation therapy and drugs is prescribed. The first-
line treatment for PDAC used to be gemcitabine, a nucleoside analog that gets 
incorporated into DNA and inhibits DNA synthesis. However, gemcitabine 
resistance is common (de Sousa Cavalcante and Monteiro, 2014). Combination 
studies of gemcitabine with the common chemotherapeutic drug nab-paclitaxel 






Figure 2. Stages in Colorectal Cancer (CRC) Development 
Early cancer stages in CRC are marked by accumulation of cancerous lesions 
called polyps (denoted in red) in normal colon cells. In this stage, the cancer is 
benign and has not spread to surrounding tissue. As the cancer progresses to 
the late adenoma stage, it starts to invade the walls through neighboring 
structures. The late adenoma stage then leads to metastasis characterized by 
with uncontrolled cell growth and spreading to the surrounding and distant 
tissue and lymph nodes.  Cellular mutations that play a critical role for 
progression in each stage are highlighted in red and described in more detail in 
the text. Adapted from Martin et al., 2018. 
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2017). Combination of a group of 4 drugs, termed FOLFIRINOX consists of 
leucovorin, 5-fluorouracil (5-FU), irinotecan and oxaliplatin showed longer overall 
median survival (11.1 months) compared to patients treated with gemcitabine 
alone (6.8 months) with no change in the quality of life (Conroy et al., 2011). In 
the FOLFIRINOX combination regimen, leucovorin is used to reduce the toxic 
effects of 5-FU (Rustum 1990). Another component of the FOLFIRINOX regimen, 
5-FU is a pyrimidine analog that primarily inhibits the enzyme thymidylate 
synthase activity by blocking thymidine synthesis and subsequent production of 
DNA. Irinotecan, a third component of the FOLFIRINOX regimen, inhibits the 
activity of topoisomerase I, an enzyme that prevents supercoiling of DNA and 
leads to double-strand DNA breakage and cell death (Chabot 1997). Lastly, 
oxaliplatin is platinum-based agent and forms platinum-DNA adducts (Raymond 
et al., 1998). Since 2011, FOLFIRINOX has been used as a first-line treatment 
for advanced metastatic PDAC, with gemcitabine prescribed as a second-line 
therapy in some cases.  
 
On the other hand, for CRC, in early stages, the available options for 
treatment includes removal of some or all parts of the colon (colectomy) with 
adjuvant chemotherapy. A part of the FOLFIRINOX regimen, namely FOLFOX 
(combination treatment of 3 drugs with 5-FU, leucovorin, and oxaliplatin) has 
shown efficacy for CRC treatment. For more aggressive tumors, targeted 
therapies such as bevacizumab [monoclonal antibody that prevents vascular 
endothelial growth factor (VEGF) activity] as well as cetuximab and panitumumab 
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[monoclonal antibody that prevents epidermal growth factor receptor (EGFR) 
activity] have been approved by the Food and Drug Administration (FDA) 
(Mundade et al., 2014). VEGF and EGFR lead to increased angiogenesis and 
cell growth respectively in CRC, and thus can serve as targets for these 
therapies.  
 
However, in addition to having a number of side effects, all the options 
listed above barely extend the life span of the patient (~3-4 months) and provide 
little chance for a cure for both these cancers. An ideal treatment strategy 
requires a combination of drugs that can simultaneously target 
upstream/downstream regulators in multiple signaling pathways and work in 
conjunction with each other to block disease progression. An important way to 
regulate signaling pathways are posttranslational modifications (PTMs) of critical 
histone and non-histone proteins in the process.  One such example is the 
transcription factor nuclear factor kB (NF-kB) that is important in inflammation 
and cancer progression in cells. Our lab recently made a significant discovery by 
identifying a novel PTM on NF-kB in the form of arginine (R) methylation, which 
led to its downstream activation (Wei et al., 2013). The enzyme implicated for this 
PTM was a member of the epigenetic enzyme family of protein arginine 
methyltransferases (PRMTs), namely PRMT5. This was an exciting finding as 
NF-kB is a well-known tumor promoting factor and is constitutively activated in 
both PDAC and CRC. Furthermore, PRMT5-mediated NF-kB methylation could 
serve as a novel mechanism underlying NF-kB activation observed in these 
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cancers. Thus, targeting PRMT5 could decrease this activation, leading to 
potential therapeutic effects. In the next sections, the critical role of NF-kB 
signaling in cancer as well as an insight into the PRMT family and PRMT5 is 
discussed further.  
 
1.2 NF-kB Signaling and Its Role in PDAC and CRC 
In mammals, the NF-kB family consists of five members: RelA (p65), 
RelB, Rel (cRel), NF-kB1 (p50 and its precursor p105) and NF-kB2 (p52 and its 
precursor p100) (Ghosh et al., 1998). All the members share a Rel homology 
domain in the N-terminus, which is essential for dimerization and binding to 
cognate DNA sequences. 
 
1.2.1 NF-kB Signaling Pathway 
The NF-kB signaling can be classified into either the canonical or the non-
canonical pathway. The canonical pathway mainly regulates the transcription of 
genes involved in inflammation, innate immunity and cell survival. On the other 
hand, the non-canonical pathway is involved in the transcription of genes 
regulating B-cell maturation, humoral immunity and lymphoid organ development. 
Though there are two pathways, the canonical pathway has been documented to 
primarily play a role in PDAC and CRC, in which an inhibitor complex named 
IkBα (inhibitor of kB alpha) sequesters p65-p50 heterodimer in an inactive state 
in the cytoplasm (Figure 3). When a cell receives extracellular signals like stress, 
cytokine binding, etc., the IkB kinase phosphorylates IkBα, leading to its release  
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Figure 3. Canonical NF-kΒ signaling pathway 
External stimuli like IL-1b binding to its receptor causes the activation of the 
complex. IkΒ kinase phosphorylates specific serine residues on IkΒα, which is 
bound to the p65-p50 heterodimer. Phosphorylation of IkΒα causes its 
degradation via the proteasomal pathway. The p65-p50 dimer then translocates 
to the nucleus and activates the transcription of its target genes. In disease 
conditions, these target genes can contribute towards the hallmarks of cancer, 




and degradation, thus freeing the p65-p50 complex, and enables it to migrate 
into the nucleus and bind the kB consensus sequences in the promoters, 
resulting in the activation of specific genes. Abnormal upregulation of NF-kB 
target genes contribute to the pathology of a number of cancers, including PDAC 
and CRC. Some examples of target genes of the canonical NF-kB signaling 
pathway that contribute to six hallmarks of cancer are: (i) inflammation: TNF 
(tumor necrosis factor), IL-1 (interleukin-1); (ii) cell survival: Bcl-2 (B-cell 
lymphoma-2), XIAP (X-linked inhibitor of apoptosis protein); (iii) angiogenesis: 
VEGF (vascular endothelial growth factor), HIF1α (hypoxia inducible factor 1-
alpha) (iv) cell death and anti-proliferative effects: Fas, p53 (v) tumor promotion 
and metastasis: MMP2/9 (matrix metalloproteinase 2/9), VCAM1 (vascular cell 
adhesion molecule 1); and (vi) proliferation: cyclin D, CDK2 (cyclin dependent 
kinase). Overall, constitutive activation of the canonical signaling pathway plays a 
crucial role in disease progression. 
 
1.2.2 NF-kB Signaling in PDAC and CRC 
Instances of canonical NF-kB pathway interacting with concurrent 
signaling pathways have been well documented in PDAC and CRC etiology. 
(Prabhu et al., 2014). In terms of PDAC, KrasG12D mutation is observed in almost 
all PDAC cases and serves as the main driver of constitutive NF-kB expression 
in PanINs and PDACs through activation of AP-1. AP-1 is a transcription factor 
that is upregulated in Kras mutated cells and causes proteasomal degradation of 
the IkB complex. Degradation of IkB leads to nuclear translocation of NF-kB and 
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activation of its target genes (Ling et al., 2012). In this context, previous research 
has shown that NF-kB pathway could upregulate the inflammatory response in 
PDAC cells via crosstalk with the Notch signaling pathway (Maniati et al., 2011). 
Even in CRC, NF-kB is constitutively activated in 60-80% cases and promotes 
cell growth, metastasis and chemotherapeutic resistance (Hai et al., 2016, 
Hassanzadeh 2011). A significant finding from our lab demonstrated that PRMT5 
activated NF-kB by symmetrically dimethylating the R residue on the p65 subunit 
of NF-kB. Additionally, we showed that PRMT5 was significantly upregulated in a 
variety of cancer tissues accessed through the GeneNote database, including in 
PDAC and CRC. To build upon this important experimental foundation, my thesis 
focuses on the potential oncogenic role of PRMT5 through methylation of NF-kB 
in the context of PDAC and CRC, as well as the effort to discover small molecule 
inhibitors to inhibit PRMT5 in these two types of deadly GI cancers. In the next 
section, I elaborate on past efforts to develop compounds that target NF-kB and 
PRMT5 respectively and justify why targeting PRMT5 could prove to be a more 
viable therapeutic option than directly targeting NF-kB. 
 
1.2.3 Current Status of NF-kB Inhibitors and Their Limitations 
NF-kB pathway is an important player in PDAC and CRC and is a known 
contributor to disease initiation and progression. Intracellular signaling gets even 
more complicated since NF-kB interacts with other pathways that are also 
deregulated in PDAC and CRC. Thus, direct targeting of NF-kB can be 
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complicated as inhibition of NF-kB activity can result in affecting multiple 
downstream signaling pathways that could be critical for normal cell function. 
 
To date, over a hundred inhibitors of the NF-kB pathway have already 
been documented, including small molecules, peptides, small DNA/RNA, viral 
proteins, and natural compounds (Prabhu et al., 2014). However, there is no 
direct NF-kB inhibitor that has been approved in humans. Various steroids and 
anti-inflammatory drugs (aspirin) were found to block NF-kB, but they showed 
pleiotropic effects. To this date, none of them have been proven to have clinical 
applications specifically in cancers. There are various factors such as poor 
bioavailability, fast metabolism and slow absorption that impede the use of these 
compounds in the clinic. Moreover, selectivity can a problem, as other signaling 
pathways that interact with NF-kB could also be affected. This can result in 
unwanted secondary effects. In the future, targeting non-redundant cytosolic 
activators of NF-kB instead of NF-kB itself could represent a better approach to 
inhibit key processes in PDAC and CRC. In this regard, discovery of PRMT5 as a 
novel activator of NF-kB widens options for therapeutic targeting in PDAC and 
CRC treatment.  
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1.3 PRMT5, a Prominent Member of PRMTs Superfamily & Its Role in PDAC 
and CRC 
As a recently identified novel activator of NF-kB, PRMT5 represents a 
potential new therapeutic target in PDAC and CRC. PRMT5 is a prominent 
member of the PRMTs superfamily, which we will elaborate on below:  
1.3.1 PRMTs Superfamily Members & Overview of Their Structures 
Over the years, several enzyme families have been discovered to be 
directly involved in a host of PTMs that affect biological function, right from early 
germline to adult human tissue. PTMs include methylation, acetylation, 
phosphorylation, ubiquitination, sumolyation amongst the major subtypes and are 
responsible for regulation of many cellular processes. However, the main focus 
of the work presented in this thesis is a member of the PRMT enzyme family that 
regulate R residue methylation PTM of proteins.  
 
A recent chemogenetic analysis predicted the possibility of up to 44 
PRMTs may be present in the human proteome (Richon et al., 2011). However, 
only nine mammalian PRMTs have been definitively characterized so far. All nine 
PRMTs are ubiquitously expressed in different types of human tissue and 
disruption in activity of these enzymes has been shown to perturb critical 
signaling pathways that are important in various diseases, including cancer (Wei 





Figure 4. Methylation pattern of PRMT family members 
Three types of methylated arginine patterns are observed in mammalian cells. 
The first is monomethylarginine (MMA), which is catalyzed by all PRMTs and 
involves addition of one methyl group on the terminal nitrogen atom of the 
arginine. Type III PRMT7 can only catalyze MMA. The second group of enzymes 
known as type I PRMTs (i.e. PRMT1,2,3,4,6,8) catalyze asymmetric 
dimethylarginine (aDMA), which involves addition of two methyl groups placed on 
the same terminal nitrogen atom of the arginine. The third and final methylation 
pattern is the symmetric dimethylarginine (sDMA), in which two methyl groups 
are placed on each of the terminal nitrogens of the arginine in a symmetric 




The 9 PRMTs are divided into three groups based on their symmetric or 
asymmetric R residue methylation pattern: type I PRMTs catalyze the formation 
of x-NG-monomethylarginine (MMA) and asymmetric x-NG, NG-dimethylarginine 
(aDMA); type II PRMTs catalyze the formation of MMA and symmetric x-NG, 
N0G-dimethylarginine (sDMA), and type III PRMTs bring about only 
monomethylation. Type I PRMTs include PRMT1, 2, 3, 4, 6, and 8, while PRMT5  
and 9 are Type II PRMTs. PRMT7 is classified as a type III PRMT (Figure 4). 
Ratios of the three types of methylation in different cell types is estimated to be 
approximately 1500:3:2:1 for Unmethylated:ADMA:MMA:SDMA (Dhar et al.,  
2013). There is a tenth form of PRMT characterized in yeast that catalyzes the 
monomethylation of an internal guanidinium nitrogen atom. However higher 
eukaryotes lack a homologue for this subtype (Zobel et al., 1998). Majority of the 
PRMTs methylate glycine (G)- and R-rich (GAR) motifs in their substrates (Boffa 
et al., 1977), with PRMT4 being the only exception in that it methylates R 
residues sequestered in proline (P)-, G- and methionine (M)-rich (PGM) regions 
(Lee et al., 2002, Cheng et al., 2007). PRMT5 can dimethylate R residues in both 
GAR and in PGM motifs (Branscombe et al., 2001; Cheng et al., 2007). These 
PRMTs, by adding mono- or dimethyl groups to R residue alter the availability of 
hydrogen donor sites on the substrate proteins as addition of methyl groups 
occupy these respective sites. Moreover, methylation leads to a change in the 
size of the protein, with either ∼14 Da (MMA) or ∼28 Da (aDMA or sDMA) added 
to its overall mass. Both of these alterations in protein structure can affect the 







Figure 5. Structures of PRMT superfamily 
All members of the PRMT have a common methyltransferase domain, denoted 
in light blue. Besides this, some members may have some distinct structures, 
such as a SRC homology 3 (SH3) domain (denoted in dark blue) in PRMT2, 
zinc finger in PRMT3 and 9 (denoted in red), F-box domain in PRMT9 (denoted 
in green) and a N-terminal myristoylation tag (denoted in pink). Adapted from 













Figure 6. Human PRMT5 structure 
PRMT5 consists of 3 major domains: TIM barrel at the N-terminus that mediates 
interactions with its cofactor methylosome protein 50 (MEP50) and promoting 
oligomerization by interacting with the catalytic domain. Rossman fold and β-
barrel mediates interactions with the methyl donor SAM and substrates 
respectively. Dimerization domain aids in formation of possible multimeric 
complexes. 
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In terms of structure, all PRMT family members share a highly conserved 
methyltransferase domain in their structure (Figure 5). The Rossman fold 
contributes to co-factor binding whereas the β-barrel mediates substrate binding 
(Cheng et al., 2005) (Figure 6). Apart from these conserved core sequences, 
variation is seen at the N- terminus with respect to the structural domains present 
in different PRMTs. For instance, interactions with other proteins are mediated by 
an SRC homology 3 domain (SH3) domain in PRMT2, a zinc finger in PRMT3, a 
pleckstrin homology (PH) domain in PRMT4 and a triosephosphate isomerase 
(TIM) barrel in PRMT5 (Schapira et al., 2014) (Figure 5). This contributes to the 
differences in the substrates and cellular functions within the members of the 
PRMT family. 
 
Amongst these, PRMT5 has emerged as one of the most promising 
therapeutic targets in cancer mainly on the basis of findings specifically from our 
lab among others (Gulla et al., 2018, Prabhu et al., 2017, Chan-Penebre et al., 
2016). Overall, the focus of my dissertation has been to understand the potential 
of PRMT5 as a novel therapeutic target for PDAC and CRC. In the following 
sections, I provide an overview about PRMT5 and its critical substrate, NF-kB as 
well as elaborate on the rationale for developing inhibitors to reduce PRMT5 
methyltransferase activity, therefore leading to the inhibition of cancer 




As a type II methyltransferase, PRMT5 is responsible for majority of 
symmetric dimethylation occurring in human tissues. Though both PRMT5 and 9 
belong to type II PRMTs, Yang et al. (2015) clearly demonstrated that PRMT5 
was responsible for majority of the symmetric dimethylation observed in cells. 
And PRMT5 and PRMT9 did not show redundancy with respect to their 
substrates.  
1.3.2A More Aspects Regarding PRMT5 Structure 
A recent review describing the known structural information regarding 
PRMT5 indicated distinct homology between species (Schapira et al., 2014). For 
instance, Caenorhabditis elegans (C. elegans), Xenopus laevis (X. laevis) and 
human PRMT5 isoforms all comprise the Rossman fold sandwiched between the 
TIM barrel at the N-terminus and a β-barrel with a dimerization domain at the C-
terminus (Figure 6).  
 
Additionally, researchers found that a glutamine residue (E444) is critical 
for its methyltransferase activity and is located in the catalytic cleft of human 
PRMT5. A phenylalanine residue (F327) has been shown to be critical for 
specifically contributing the symmetric dimethylation activity (Sun et al., 2011). 
Furthermore, mutation of F327 to M residue led PRMT5 to have both symmetric 
and asymmetric dimethylation activity, indicating that the steric interactions that 
occur at the F327 site play a crucial role in determining the specific symmetric 
dimethylation pattern of PRMT5. 
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1.3.2B PRMT5, Global Biological Functions, and Its Role in Cancer  
PRMT5 is widely expressed in mammals and is universally found in embryonic 
as well as adult tissues (Figure 7). It has a wide-ranging role in terms of its 
substrates and the downstream functions that are affected. A complete list of 
known PRMT5 substrates is illustrated in Table 1. In fact, PRMT5 is very critical 
in early development, as previous work has shown that PRMT5 null mutants 
were embryonic lethal in mice due to an elimination of pluripotent stem cells in 
the blastocyst (Tee et al., 2010). Moreover, PRMT5 is also required for cell 
proliferation of human embryonic stem cells (Gkountela et al., 2014). These 
cellular functions of PRMT5 are regulated via methylation of its substrates. 
Specific PRMT5 substrates include several histone proteins. For instance, the 
aforementioned biological functions, PRMT5 has recently been shown to 
methylate transcription factors, including NF-kB (Wei et al., 2013), which we 
described in Section 1.2, and other examples, which we will further elaborate on 
histones H2A and H4 are methylated on R3 during germ cell development. 
Histone H3 is methylated on the R8 which may repress transcription and 
symmetric dimethylation of H3R2 supports euchromatin maintenance (Migliori et 
al., 2012). In addition to histone proteins, other PRMT5 substrates include small 
nuclear ribonucleoproteins SmD1 (SNRPD1) and SmD3 (SNRPD3) and B/B’, all 
of which are required for spliceosomal assembly and biogenesis (Brahms et al., 
2001; Meister et al., 2001). PRMT5 can also methylate a domain in C-terminus of 
RNA polymerase II (RNAP II) to facilitate the resolving of RNA-DNA hybrids, a 
step that is critical for termination of transcription (Zhao et al., 2016). 
22 
Interestingly, PRMT5 has also been shown to play a critical part in adult 
hematopoiesis as PRMT5 deletion led to a complete loss of both hematopoietic 
stem cells as well as progenitor cells in the bone marrow (Liu et al., 2015). This 
suggests a possible role of PRMT5 in development of blood cell lineage, a crucial 
cellular function. Related to the role of PRMT5 within the bone marrow, another 
study highlighted that PRMT5 could activate osteoclast differentiation and 
inhibition of PRMT5 partially suppressed this process (Dong et al., 2017). 
Osteoclast differentiation often occurs in conjunction with activation of 
inflammation-related pathways and thus provides evidence of a critical link 
between PRMT5 and inflammation in cells. Clearly, PRMT5 can play an 
important role in regulating the function of a wide variety of histone and non-
histone proteins and in turn have direct and indirect downstream effects on 
critical signaling pathways and hence has an emerged as a protein of interest 
with potential implications in a diverse set of diseases, including cancer. 
 
1.3.2C PRMT5 in Cancer 
Recent research has highlighted the contribution of PRMT5 in various 
types of cancer. Symmetric dimethylation of H2AR3, H3R2, H3R8 and H4R3 can 
affect cellular proliferation and differentiation in leukemia and lymphoma cells. 
Methylation at these sites is associated with decreased transcription of several 
genes such as RB, ST7, and NM23 (Pal et al., 2004, Wang et al., 2008). 
Furthermore, in chronic myelogenous leukemia, silencing PRMT5 eliminated 














































































































































Table 1. Known PRMT5 substrates and methylation sites 
PRMT 
SUBSTRATE 
KNOWN SITE CITATION 
ASH2L R296 Butler et al., 2011 
CBP-1 R234 Yang et al., 2009 
CF I(m)68 GAR Motif Martin et al., 2010 
EBNA GAR Motif Shire et al., 2006; Liu et al., 2013 
EGFR R1175 Hsu et al., 2011 
FEN1 R192 Guo et al., 2010 
H2A R3 Tee et al., 2010 
H3 R2 Yuan et al., 2012; Tsai et al., 2013 
H3 R8 Pal et al., 2004 & 2007 
H4 R3 Yue et al., 2013; Girardot et al., 2014 
HOXA9 R140 Bandyopadhyay et al., 2012 
LSm4 -- Brahms et al., 2001 
NaV1.5 -- Beltran-Alvarez et al., 2013 
NF-kB R30, R35, R174 Wei et al., 2013; Harris et al., 2014 & 
2016 
Nucleolin -- Guderian et al., 2011 
Nucleoplasmin GAR Motif Wilczek et al., 2011 
p53 R333, 335, 337 Jansson et al., 2008  
PDCD4 R110 Powers et al., 2011  
RNAPII R1810 Zhao et al., 2016 
RPS10 R158, 160 Ren et al., 2010 
RUVBL1 R205 Clarke et al., 2017 
SKI R8 Tamiya et al., 2018 
SmD1  GAR Motif Brahms et al., 2001 
SmD3 GAR Motif Brahms et al., 2001 
SPT5 R698 Kwak et al., 2003 
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therapies (Jin et al., 2016). Additionally, PRMT5 mutations are found in a wide 
range of cancers according to The Cancer Genome Atlas project database (Gao 
et al., 2013). PRMT5 has also been dubbed as a “potential oncoprotein” as it 
upregulates factors involved in cell cycle regulation like G1 cyclins and cyclin 
dependent kinases as well as the phosphoinositide 3-kinase (PI3K)/AKT 
signaling pathway (Wei et al., 2012). Gu et al. demonstrated that PRMT5 is 
essential for the growth of solid tumors like lung cancer cells by showing that 
PRMT5 knockdown in lung adenocarcinoma A549 cells partially downregulated 
the fibroblast growth factor receptor signaling pathway, which not only reduced 
cell growth and tumor (Gu et al., 2012) but also promoted metastasis (Jing et al., 
2018), the latter phenotype reportedly through PRMT5-mediated regulation of 
miR-99. This showed that PRMT5 was capable of mediating tumor growth and 
metastasis through epigenetic regulation of micro RNAs. PRMT5 expression was 
also significantly upregulated in hepatocellular carcinoma tissue and correlated 
with higher cell proliferation, possibly via the Wnt/β-catenin signaling pathway. 
Silencing PRMT5 downregulated β-catenin expression and its downstream 
effector cyclin D1, thereby suggesting a link between PRMT5-mediated β-
catenin-driven cell proliferation in these cells (Zhang et al., 2015). Furthermore, 
in hepatocellular carcinoma cells, the ERK signaling pathway was also shown to 
be regulated by PRMT5, and subsequently had a profound effect on cell 
proliferation in these cells (Jiang et al., 2018). Thus overall, PRMT5 plays a 
critical role in promoting the cancer phenotype through varied signaling pathways 
in hepatocellular carcinoma. Another critical signaling pathway, TGF-β has also 
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been shown to be regulated by PRMT5 via coupled arginine methylation of 
histones H3 and H4, leading to subsequent transcriptional activation and 
repression of key regulatory genes involved in cancer respectively (Chen et al., 
2017).  
 
The well-known tumor suppressor gene p53 has also been shown to be a 
substrate of PRMT5 in osteosarcoma cells. For instance, ectopic expression of 
PRMT5 in osteosarcoma cells enhanced p53-mediated DNA damage repair 
(Jansson et al., 2008). This is especially harmful in cancers as most 
chemotherapeutic drugs work on the principle of inducing DNA damage in cancer 
cells to cause cell death. Induction of DNA repair response reduces the efficacy 
of the chemotherapeutic drug, possible contributing to drug resistance. 
Furthermore, gene expression data also showed that PRMT5 is upregulated in a 
number of cancers including breast, cervix, liver, prostate, lung, ovary and 
bladder, and particularly in PDAC and CRC, which are the disease focus of my 
work (Wei et al., 2013). Additionally, ulcerative colitis (a risk factor for CRC) was 
associated with increased local PRMT5 expression by regulating the activity of 
regulatory T cells (Zheng et al., 2017), indicative of its link to immune function in 
colon cells. Finally, as mentioned in the previous section, a complete list of 
known substrates with methylation mark introduced by PRMT5 is illustrated in 
Table 1. Several of the substrates have already been described in this chapter 
as important players in cancer such as EGFR, histones and p53 amongst others. 
Based on this compilation of its substrates, it is clear that PRMT5 can play an 
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important role in regulating the function of a wide variety of histone and non-
histone proteins with critical implications in cancer. 
 
In this thesis, we have focused on the PRMT5 substrate: NF-kB, based on 
our discovery that PRMT5 activates NF-kB through R30 methylation of the p65 
subunit (Wei et al., 2013). This finding has opened up additional possibilities of 
targeting PRMT5 as a novel approach to inhibit NF-kB, apart from the ones listed 
above. Since NF-kB is a well-known tumor promoting factor and is constitutively 
activated in both PDAC and CRC, as described in Section 1.2, inhibiting 
PRMT5-mediated NF-kB activation could offer the hope of new approaches to 
combat PDAC and CRC as well as other cancers. In the future, it will be 
interesting to explore the crosstalk between signaling pathways and specific 
substrates regulated by PRMT5 and possible implications in cancer as well as 
how they could be therapeutically targeted to design an effective solution for 
patients suffering from this deadly disease. 
 
1.3.2D Promise of Developing PRMT5 Inhibitors  
Epigenetic enzymes capable of catalyzing PTMs have emerged as an 
attractive target in recent times, with histone deacetylase (HDAC) enzyme family 
inhibitors such as Vorinostat and Romidepsin already approved by FDA for use 
in lymphoma patients. Inhibitors of other HDAC family members and sirtuins 
(protein deacetylases) have shown early clinical promise (Eckschlager et al., 
2017). Unfortunately, the clinical success seen in blood cancers has not been 
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replicated in clinical trials of HDAC inhibitors in solid tumors (Slingerland et al., 
2014; Qiu et al., 2013). The exact reasons have not been established for this 
dichotomy, but differential drug accessibility and tumor microenvironments 
potentially could play a role in many drugs to work better in liquid tumors as 
compared to solid tumors. Other epigenetic enzyme families with previously 
unexplored potential as targets are now being considered in drug discovery for 
solid tumors.  
 
With regards to PRMT5, there are no known inhibitors in clinical trials. In 
that regard, my thesis focuses on the role of PRMT5 as a therapeutic target, at 
least via reducing the constitutive activation of NF-kB observed in PDAC and 
CRC. While we were developing inhibitors of PRMT5, a PRMT5 inhibitor, 
EPZ015666 was identified by Epizyme Inc. and showed high efficacy in inhibiting 
PRMT5 in mantle cell lymphoma disease models (Chan-Penebre et al., 2016). 
Since we were currently developing our own unique inhibitor at the time and 
EPZ015666 was commercially available for purchase, we used it in our own 
studies to compare its activity against our inhibitor in PDAC and CRC models, and 
these results have been included in Chapters 4 and 5.  
1.4 Summary and Hypotheses 
Previous studies have shown that PTMs of the p65 subunit like acetylation 
and phosphorylation can modulate NF-kB activity. However, methylation was not 
shown to affect its functional role until now. Our lab was the first to show that NF-
kB activity can be modified by PRMT5. Symmetric dimethylation by PRMT5 
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leads to NF-kB activation and increased transcription of the NF-kB target genes. 
This suggests a mechanism by which PRMT5-mediated methylation of p65 could 
promote inflammation and anti-apoptotic responses in PDAC and CRC via 
upregulation of NF-kB target genes. This is also supported by the fact that 
expression of PRMT5 is greatly overexpressed in PDAC and CRC. Thus, PRMT5 
can act as a tumor promoting factor, at least with respect to NF-kB activation in 
PDAC and CRC cells and therefore has great potential to be used as a novel 
drug target to treat these diseases.  
 
Furthermore, we have adapted the AlphaLISATM (Amplified Luminescent 
Proximity Homogeneous Assay-Linked immunoSorbent Assay) technique to 
sensitively quantify the levels of PRMT5 methylation that can be used to screen 
for small molecule inhibitors of PRMT5 activity. AlphaLISA assay is a bead-
based chemiluminescent screen which recognizes the dimethyl tag specific to 
PRMT5 and the amount of detected signal is proportional to the amount of 
methylation of a substrate peptide by PRMT5. Hence this assay allowed us to 
quantify the enzymatic activity of PRMT5.  
 
Overall, this research proposes a novel hypothesis that PRMT5 can 
contribute to PDAC and CRC pathogenesis, at least partly via NF-kB activation 
and can be used a novel drug target for their treatment. In this regard, we used 
the AlphaLISA technique to screen for drugs that can possibly benefit for PDAC 
and CRC patients.   
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CHAPTER 2. METHODS 
2.1 In Vitro Experiments 
2.1.1 Cell Lines & Materials 
Pancreatic control (HPNE) and cancer cell lines (PANC1, MiaPaCa2 and 
AsPC1) were a kind gift from Dr. Murray Korc from Indiana University School of 
Medicine (IUSM). The normal colon cell line (FHC) and CRC (HT29, HCT116, 
DLD1) cell lines were purchased from the American Type Culture Collection 
(ATCC). All pancreas-derived cell lines were grown in Dulbecco’s Modified 
Eagle Medium (DMEM) (GE Healthcare), supplemented with 1% of 
penicillin/streptomycin and 5% fetal bovine serum (FBS). CRC cells were 
maintained in Roswell Park Memorial Institute Medium (RPMI 1640) (GE 
Healthcare), containing 1% penicillin/streptomycin and 5% FBS, while FHC 
cells were cultured under the same conditions with further addition of 25mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 10ng/ml cholera 
toxin, 0.005 mg/ml insulin, 0.005 mg/ml transferrin and 100 ng/ml hydrocortisone. 
All cell lines were cultured at 37°C under 5% CO2 and used between passages 2 
to 5. Cell lines were authenticated using 9 Marker STR Profile by IDEXX 
Bioresearch. 
 
For AlphaLISA, the methyl group donor SAM (S-adenosyl methionine) was 
purchased from New England Biolabs. Unmethylated biotinylated histone H4 
peptide substrate at arginine (R) 3 (unmeH4R3) was obtained from AnaSpec. 
The 23-amino acid sequence of H4R3 peptide was as follows: 
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SGRGKGGKGLGKGGAKRHRKVLRGG-K(biotin)-NH2, with the third arginine 
site available for demethylation as per the assay protocol. For screening, 
dimethyl sulfoxide (DMSO) stock of library compounds comprising of 
approximately 10,000 small molecule inhibitors purchased from ChemDiv and 
another 10,000 group of compounds with pure natural products, semi-synthetic 
natural products and reported bioactives collectively purchased from Analyticon 
Discovery, MilliporeSigma and Microsource Discovery Systems Inc. The 
compound libraries were stored at -80°C. Anti-methyl-H4R3 AlphaLISA beads, 
Streptavidin-tagged Donor beads, 1X Epigenetics buffer, TopSeal™-A film, 
OptiPlate™-384 white opaque plates, and EnVisionÒ Multilabel Reader were 
obtained from PerkinElmer.  
 
2.1.2 Generation of Stable PRMT5 Overexpressing and Knockdown Cell Lines  
Flag-tagged WT-PRMT5 or shPRMT5 cDNA was generated by from total 
mRNA derived from 293 cells. After confirming the insertion by sequencing, the 
cDNA constructs were cloned into pLVX-IRES-puro vector (Lu et al., 2010). A 
pool of 5 shRNAs against PRMT5 (Sigma-Aldrich) were used to ensure efficient 
knockdown of this target. The respective lentiviral plasmids containing empty 
vector, WT-PRMT5 or shRNAs were transected into a 293T packaging cell line 
with high efficiency to produce viral preps that were used to infect PANC1 or 
HT29 cells. Upon 48h of infection, cells were exposed with 1μg/mL of puromycin, 
allowing further selection, as the lentiviral vector contains a puromycin resistance 
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gene. Western Blotting using PRMT5 Ab was used to confirm the overexpression 
and knockdown in these cells.  
 
2.1.3 Western Blotting  
Cultured cells were pelleted by scraping them in 1X phosphate buffered 
saline (PBS), followed by centrifugation at 5,500 rpm for 5 min. The supernatant 
was aspirated, and pellets were frozen overnight at -80°C. Next day, RIPA buffer 
[10mM Tris-Cl pH 8.0, 1mM EDTA, 1% Triton X, 0.1% sodium deoxycholate, 
0.1% SDS (sodium dodecyl sulfate; electrophoresis grade), 14mM NaCl, 1mM 
PMSF] was added to the pellets, combined with intermittent vortexing and 
incubation on ice to promote lysis. The cells were pelleted at 5,500 rpm for 5 min. 
The supernatant for each sample was then tested for its protein concentration 
using the Protein Assay Reagent (Biorad) and absorbance values measured 
using a Genesys 10S Vis spectrophotometer (Thermo Fisher Scientific), to 
ensure equal loading of the samples on the gel. Prior to running the samples on 
the gel, equal protein concentrations are mixed with 2X SDS sample loading 
buffer [100mM Tris-Cl, pH 6.8, 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 
20% (v/v) glycerol, 200mM β-mercaptoethanol]. Each sample mixture was then 
heated at 100°C for 5 min and gently spun down to gather all the sample at the 
bottom of the tube. These protein samples were then run on a 10% SDS-PAGE 
(sodium dodecyl sulfate polyacrylamide gel electrophoresis) gel and then 
transferred overnight to a polyvinylidene fluoride (PVDF) membrane (Fisher 
Scientific) at 4°C. Primary antibodies for anti-PRMT5 (Abcam), anti-Flag 
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(Sigma-Aldrich), anti-dimethyl arginine motif (sdme-RG) (Cell Signaling 
Technology), symmetric dimethylation at R30 subunit of p65 (detected by 
generating a customized polyclonal primary antibody in collaboration with 
GenScript Inc), β-actin (Sigma-Aldrich) and their corresponding secondary 
antibodies were used. The enhanced chemiluminescence (ECL) detection 
method (PerkinElmer) was conducted to detect the protein signal. 
 
2.1.4 Immunohistochemistry Assay  
Pancreatic and colon cancer tissue microarrays with matched normal 
adjacent controls were acquired from US Biomax Inc. The tissue microarrays 
were blocked using protein-blocking solution (Dako Corp.) for 30 min. All 
subsequent staining steps were performed using the Dako FLEX SYSTEM and 
an automated Immunostainer. Incubations were carried out at room temperature 
(R.T.) and Tris buffered saline containing 0.05% Tween 20, pH 7.4 (Dako Corp.) 
was used for all the washes and diluents. Anti-PRMT5 primary antibody 
(Abcam) was used to detect PRMT5 localization. Horseradish peroxidase-
conjugated secondary antibody was then used, followed by addition of the 
chromogen, which formed a brown precipitate at the binding site of secondary 
antibody. Imaging was done using Aperio whole slide digital imaging system. 
The system imaged all slides at 20X magnification. 
 
2.1.5 Cell Proliferation Assay 
Stable PANC1 and HT29 cells with WT-PRMT5, shPRMT5 and empty 
vector control overexpression respectively were seeded in triplicates in 6-well 
34 
plates at 2X104 cells/well. Cells were trypsinized at day 3, 5, 7, 9 and counted 
using a hemocytometer chamber. 
 
2.1.6 Anchorage-Independent Growth Assay 
2.5% and 1.25% agar were used to prepare the bottom and top layers of 
the soft agar, respectively. The bottom agar was added to each well of a 6-well 
plate. 2X105 cells for each cell line were then mixed into top agar solution and 
layered on top of the bottom layer. The plates were incubated for 10-20 days at 
37°C and 5% CO2. Images were captured using a Canon EOS Rebel T3i Digital 
SLR camera and quantification of colony size and number was performed using 
ImageJ. 
 
2.1.7 Migration Assay  
Migration assay was conducted using Boyden chambers. 8μm pore size 
cell culture inserts (Corning) were placed in a 24-well plate. Each chamber was 
coated with gelatin on the side facing the lower chamber. 2X105
 
cells were 
suspended in serum-starved media in the upper chamber of the well. 
Corresponding serum rich media was added to the lower chamber. Migrated 
cells were fixed using 4% formaldehyde followed by crystal violet staining and 
counting using a microscope at 20X magnification. The images were captured 
using a Canon EOS Rebel T3i Digital SLR camera. 
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2.1.8 NF-kB luciferase Assay  
The NF-kB luciferase construct p5XIP10 (containing five tandem copies 
of the NF-kB site from the IP10 gene) was transfected transiently in the cell lines 
using Lipofectamine™ LTX Reagent and PLUS Reagents (Thermo Fisher 
Scientific). Luciferase activity was assayed 48h later (with or without PRMT5 
small molecule inhibitor treatment, if applicable) by using the Luciferase Assay 
System with Reporter Lysis Buffer kit (Promega) as per the manufacturer’s 
instructions. The activity was measured using a Synergy H1 Multi-Mode Reader 
(BioTek Instruments Inc). 
 
2.1.9 Quantitative PCR   
Cells were cultured to 90% confluence (followed by treatment with 
compound, if applicable) and total RNA was isolated using Trizol as described 
previously (Wei et al., 2013). cDNA was prepared from total RNA by reverse-
transcriptase PCR using the SuperScript III First-Strand Synthesis System 
(Invitrogen). qPCR was carried out using FastStart Universal SYBR Green 
Master ROX kit (Roche). Primers were designed by Primer Express 3.0 software 
and are listed in Appendix A. 
 
2.1.10 PRMT5 Enzyme Purification 
Flag-tagged PRMT5 enzyme was purified from 293 cells overexpressing 
Flag-PRMT5 by co-immunoprecipitating with Flag beads (MilliporeSigma). 293-
Flag-PRMT5 cells were cultured in 15cm plates at ~90% confluency per plate. 
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After washing the cells with 1X PBS, the cells were spun down at 1,200 rpm for 
10 min at 4°C. The pellets were lysed by adding lysis buffer (50mM Tris-HCl, pH 
7.4, 150mM NaCl, 1mM EDTA, 100nM phenylmethanesulfonyl fluoride (PMSF), 
0.5M Na3NO4, 1% Triton X-100 and protease inhibitor tablets) and vortexing 4-5 
times over a period of 20 min. The lysed cells were spun at 3,400 rpm for 30 min, 
and the supernatant was transferred to the prewashed Flag beads suspended in 
1X cold PBS. The lysed cells/beads mixture was rotated at 4°C. After overnight 
incubation, the beads were spun down and washed 4 times using 1X wash buffer 
(50mM Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 0.5% Triton X-100). After the 
washing steps, the beads were mixed with Flag peptide and rotated for 1 h at 
4°C, then spun down. Supernatant (the PRMT5 enzyme product) was added with 
storage buffer (40mM Tris, 110mM NaCl, 2.2mM KCl, 3mM dithiothreitol (DTT), 
20% glycerol), and used immediately for the AlphaLISA assay or aliquoted at -
80°C until further use. 
 
2.1.11 AlphaLISA-based H4R3me2 Detection Assay 
The AlphaLISA reaction was run in 384-well white opaque plates with a 
total reaction volume of 30μl. All the parameters of the assay were determined 
using standardized conditions by testing 10-100nM of unmeH4R3 and of 0.2-
4000μM SAM. In the pilot experiments as well as the Z’ test, the following 
protocol was used: the biotinylated unmeH4R3 substrate stock as well as the 
SAM stock was diluted using milliQ water with final concentrations of 30nM and 
100nM respectively in the reaction well. The PRMT5 enzyme prep was diluted at 
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1:10 ratio in Assay buffer (30mM Tris, pH 8.0, 1mM DTT, 0.01% Bovine serum 
albumin, 0.01% Tween-20) before being used. 10μl of unmeH4R3:SAM mixture 
and 10μl of diluted enzyme stock were mixed in each well and incubated at R.T. 
for 1 h. Following this step, the Acceptor bead stock (with an antibody tag 
specific for H4R3me2) was diluted 1:50 using 1X Epigenetics buffer to a final 
concentration of 20μg/ml. 5μl of the diluted bead stock was dispensed in each of 
the reaction wells. After incubation with the Acceptor beads for 1 h at R.T., the 
streptavidin-coated Donor bead stock (specific for the biotinylated substrate) was 
diluted at 1:50 using 1X Epigenetics buffer to a final concentration of 20μg/ml, 
and 5μl was dispensed in each of the reaction wells (Table 1). Following 
incubation with Donor beads for 30 min in the dark, the plates were immediately 
read using the “Alphascreen” filter in the EnVisionÒ Reader. To assess 
background of the reaction in the negative control wells, all the conditions were 
the same except 10μl of 1X assay buffer was added instead of enzyme stock. 
 
2.1.12 High-throughput Screening 
For the HTS, we used the optimized protocol as described in Table 1. 
Briefly, 10μL of the substrate 2X mix (60nM unmethylated peptide, 200μM SAM 
in MilliQ water) was dispensed using Multidrop into each well of the assay plates. 
The final reaction concentration was 30nM unmeH4R3 peptide and 100μM SAM. 
Next, 250nL of 1mM DMSO stock of the library compounds was transferred to 
columns 1-20, with a final compound concentration of 12.5μM and final DMSO of 
1.25% in each well. 5% DMSO/water (1% DMSO final) was added to column 21-
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24 to keep the DMSO concentration consistent with the wells in which the 
compounds were added. Next, 10μL of enzyme (ten-fold dilution of the enzyme 
prep in assay buffer) was dispensed to columns 1-22 using MultiFlo in each 
plate. At the same time, 10μL of the 1X assay buffer was added to columns 23-
24 in each plate. Thus, columns 21-22 serve as positive “maximum signal” 
controls (no inhibitor, with PRMT5 enzyme added) and columns 23-24 act as 
“background signal” controls (no inhibitor, no enzyme added). Columns 1-20 in 
each plate had the different inhibitors added, with 1 replicate for each compound 
in the library. The plates were incubated at R.T. for 1 h. 5μL of anti-H4R3me2 
Acceptor beads (1:50 dilution of the 5mg/mL stock in 1X Epigenetics Buffer) were 
then dispensed using MultiFlo into each well of the assay plates. The plates were 
incubated at R.T. for 1 h. 5μL of Donor beads (1:50 dilution of the 5mg/mL stock 
in 1X Epigenetics Buffer) were dispensed using MultiFlo into each well of the 
assay plates. The plates were incubated at R.T. for 30 min followed by Alpha 
signal reading on EnVisionÒ reader.  
 
We conducted two rounds of HTS as described: the first round included a 
set of 10,000 chemical inhibitor library from ChemDiv. For the second round, we 
used the following libraries: (1) LOPAC 1280 (2) Spectrum 2400 (3) AnalytiCon 
MEGx 1000 (4) AnalytiCon NATx 5000. LOPAC and Spectrum compound 
libraries comprise of known drugs, natural products and reported bioactives. 
AnalytiCon MEGx and NATx contain pure natural products and semi-synthetic 







Table 2. Protocol for high throughput screening for PRMT5 AlphaLISA 
assay 
Step Parameter Value Description 
1 Dispense substrate & 
cofactor 
10μl 2X mix of SAM/peptide 
2 Dispense compounds 250nL 80X compound (1.25% (v/v) 
DMSO) 
3 Dispense enzyme 10μl 2X PRMT5 enzyme 
4 Incubation time 1h RT, sealed 
5 AlphaLISA Acceptor beads 5μl 1:42 dilution of Acceptor beads mix 
6 Incubation time 1h RT, sealed 
7 AlphaLISA Donor beads 5μl 1:42 dilution of Donor beads mix 
8 Incubation time 0.5h R.T., sealed 
9 Assay readout 615nm EnVision plate reader; Alphascreen 
mode 
Step Notes: 
1. Final concentrations are 30nM Biotin-unmeH4R3, 100μM SAM prepared in 
MilliQ water. 
2. Final compound concentration: 12.5μM; columns 21-24 do not have 
compound and have only DMSO/water with a final DMSO concentration at 
1.25%. 
3. Columns 23 and 24 only has no enzyme, prepared in enzyme reaction 
buffer. 
4. Plates sealed with adhesive film and covered with aluminum foil. 
5. Final concentration is 20μg/ml for Acceptor beads mix, prepared in the dark 
using 1X Epigenetics buffer. 
6. Plates sealed with adhesive film, covered with aluminum foil and kept in 
dark. 
7. Final concentration is 20μg/ml for Donor beads mix, prepared in the dark 
using 1X Epigenetics buffer. 
8. Plates sealed with adhesive film, covered with aluminum foil and kept in 
dark. 
9. Alphascreen (615nm) emission filter 
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2.1.13 Quenching Experiment 
In this assay, the incubation and assay conditions were relatively similar to 
the HTS assay described above. The major differences were: (1) histone H4 pre-
methylated at arginine 3 (Biotin-H4R3me2) (AnaSpec) was used as a substrate 
at a final concentration of 15nM; (2) No PRMT5 enzyme or unmethylated 
substrate was included in the experiment, and (3) The plate design differed as 
follows: the first two columns did not have any compound (positive control). 
Columns 1-22 had pre-methylated Biotin-H4R3me2 substrate. The last two 
columns did not have this pre-methylated substrate (negative control; 
background). Diluted AlphaLISA beads (Acceptor and Donor) were added to 
each well. 
 
2.1.14 MTT [(3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide)] 
Assay  
Cells were seeded at 60% confluence in Corning® Costar® clear flat-
bottom 96-well plates and titrated with different dosages of respective 
compounds. After incubation for 4 days, 10μl of MTT dye (Sigma-Aldrich) was 
added directly to each well. The dye was incubated with the cells for 2 h at 37°C. 
The media was then aspirated and 10μl of DMSO was then added to each well. 
The colorimetric dye was quantified using Synergy H1 Multi-Mode Reader from 
BioTek Instruments Inc. 
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2.1.15 3D colony Formation Assay 
500 cells per well were seeded in media containing 3% Reduced Growth 
Factor (RGF)-Matrigel (BD Biosciences) in a Corning® Costar® ultra-low 
attachment multiwell plate and allowed to form colonies. PR5-LL-CM01 stocks 
made in 100% DMSO were diluted using 3% RGF-Matrigel media and added to 
the respective wells, in a 2-fold serial dilution concentration range from 0.75 to 
25μM on days 3 and 7 after seeding. On day 7 post first drug treatment, the cells 
were stained using Alamar blue dye (Fisher) and quantified using a Synergy H4 
Multi-Mode Reader (BioTek Instruments Inc). 
 
2.1.16 Co-immunoprecipitation Experiment  
293 cells with stable overexpression of Flag-p65 protein, were treated with 
20μM of PR5-LL-CM01 for 24 h. After the cells were lysed using the lysis buffer 
(50mM Tris-HCl, pH7.4, 150mM NaCl, 1mM EDTA, 1% Triton X-100, 100nM 
PMSF, 0.5M Na3NO4) and vortexing, p65 was then pulled down with anti-Flag-
M2 beads. The samples were then run on a 10% protein gel and probed with 
anti-symmetric dimethyl arginine motif (sdme-R) antibody (Cell Signaling 
Technology), to check for dimethylation levels of p65. 
 
2.1.17 Structural Analysis and Docking Experiments  
This experiment was done in collaboration with Dr. Ozlem Demir at the 
University of California, San Diego under the guidance of Dr. Rommie Amaro. 
For docking, chain A of PRMT5 protein in 4X61.pdb from the Protein 
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Databank was used. All docking experiments were performed by Glide 
program (version 6.8) of the Schrodinger suite 2015-3 in standard precision 
mode (Halgren et al.,2004; Freisner et al., 2004). The protein was prepared for 
docking by the Protein Preparation Wizard of Schrodinger suite 2015-3 (Sastry et 
al., 2013). Control docking experiment was performed by deleting the ligand 
PR5-LL-CM01 or EPZ015666 from the crystal structure while keeping the 
ligand SAM. The control docking experiment was able to reproduce the 
binding pose of EPZ015666 seen in the crystal structure. An additional docking 
experiment was done by docking EPZ015666 into the PRMT5 active site after 
deleting the SAM ligand as well as EPZ015666 from the active site. PR5-LL-
CM01 was docked into the PRMT5 active site in two separate docking 
experiments. In one experiment, the compound was docked into the PRMT5 
active site in which EPZ015666 is deleted while SAM is kept. In the other 
experiment, PR5-LL-CM01 was docked into the completely empty active site in 
which both SAM and EPZ015666 were deleted. All the figures for this 
experiment were prepared with Maestro version 10.3. 
 
2.1.18 Methyltransferase Assay for PRMT5 Family Members 
The specificity of inhibition by PR5-LL-CM01 against the enzymatic activity 
of protein arginine methyltransferase family members was analyzed using the 
HotSpot radioisotope-based platform (Reaction Biology Corp) as described 
previously (Horiuchi et al., 2013). PRMT family members 1,3,4,5,6,8 were included 
in the study based on the availability with Reaction Biology Corp offering the 
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methyltransferase screening service. Briefly, PR5-LL-CM01 was incubated with a 
protein arginine methyltransferase, substrate, and tritium-labeled SAM. The PR5-
LL-CM01 stock solution was prepared in DMSO at 10mM. PR5-LL-CM01 was 
tested at 1, 10, 25, 50 and 100μM. The methyltransferase inhibitor SAH (S-(5'-
Adenosyl)-L-homocysteine) was used as a positive control. All reactions were 
carried out with 1μM tritium-labeled SAM and 5μM of peptide substrate. The 
assays were performed using Reaction buffer (50mM Tris-HCl, pH 8.5, 5mM 
MgCl2, 50mM NaCl, 0.01% Brij35, 1mM DTT). Reactions were performed for 1 h 
at 30°C. Radiolabeled methylated product was detected using a filter-binding 
method. Curve fits and IC50 determination were executed as described previously 
(Horiuchi et al., 2013). 
 
2.1.19 Sepharose Bead-Based Binding Study 
CNBr-activated Sepharose 4B beads (GE Healthcare) were used to 
conjugate PR5-LL-CM01 in order to measure the binding interaction of PR5-LL-
CM01 with PRMT5.  The first step involved activating beads by dissolving in 
1mM HCl followed by washing with 1mM HCl in a 0.22µM filter. 10μmol of PR5-
LL-CM01 or cycloheximide (CHX) were dissolved in coupling buffer respectively 
(0.1M NaHCO3, pH 8.3; 0.5M NaCl). CHX was used as a non-specific protein 
that would not bind to the beads. The compound and bead solutions were then 
mixed together in a stoppered vessel in a round bottom tube and rotated the 
tubes overnight at 4°C. Only coupling buffer was added to the Beads only control 
tube. Next day, the beads were washed with coupling buffer and any remaining 
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active groups were blocked with 0.1M Tris HCl, pH 8.0 overnight at 4°C. Next 
day, the beads were washed with at least three cycles of alternating pH of 0.1M 
sodium acetate/acetic acid, pH 4.0 containing 0.5M NaCl and 0.1M Tris HCl, pH 
8.0 containing 0.5M NaCl. Same day, 293-PRMT5-Flag cell lysates were 
prepared by washing and scraping the cells into cold 1XPBS per plate. The cells 
were pelleted by spinning at 1,200 rpm for 10 min at 4°C. Lysis buffer (50mM Tris 
HCl, pH7.4; 150mM NaCl; 1mM EDTA; 1% Triton X; with protease inhibitors) ~2-
fold volume of the pellet size) was added to each tube for cell lysis. Cell lysate 
was collected after spinning at 5,500 rpm for 10min. Before adding the cell lysate 
to the beads, the beads were blocked with non-fat milk in lysis buffer (no 
inhibitors) for 1 h at R.T. We tested several blocking conditions as highlighted in 
Figure 36A. After spinning down the beads, they were incubated with cell lysate 
by rotating at 4°C overnight.  The next day, beads were spun down at 13,000 
rpm for 40 sec and unbound proteins were removed by washing beads 4 times 
with washing buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 0.5% 
Triton X-100) at 4°C.  Finally, after last wash, the beads were spun down at 
13,000 rpm, 40 sec and all the residual liquid on top of the beads was removed 
carefully to avoid accidental aspiration of the beads. These samples were run on 
an SDS-PAGE gel and Western blotting was carried out as previously described 
in Section 2.1.3 by probing with anti-PRM5 antibody and corresponding 




2.1.20 Isothermal Calorimetry (ITC)  
The reaction system for ITC consists of a sample well and an injection 
syringe. 350μl of 100-200μM of PRMT5 was added to the sample well. 10 X 15 
cm plates with 293-PRMT5-Flag cells were used for enzyme purification as 
described in Section 2.1.10. 100μl of 5mM of PR5-LL-CM01 (dissolved in 
DMSO) was placed in the injection syringe. Both the components were dissolved 
in 1X ITC buffer (1XPBS, 110mM NaCl, 2.2 mM KCl, 3mM DTT) such that the 
final concentrations of the buffer in both the well and syringe were equalized to 
avoid buffer mistmatch. The reaction system was set at 25°C. The inhibitor was 
then automated to set up 50 serial injections every 5 minutes of 2μl each from 
the injection loop into the sample well. A curve with heat changes in the system 
with every successive injection over time was obtained at the end of the 
experiment. 
 
2.1.21 Cellular Thermal Shift Assay  
PANC1 or HT29 cells were cultured to 95% cell density in 4 X 10 cm 
plates per cell line. 2 plates were treated with DMSO vehicle and 2 plates were 
treated with either 20μM PR5-LL-CM01 for PANC1 or 40μM PR5-LL-CM01 for 2 
h at 37°C. Cells were then trypsinized and resuspended in R.T. 1X PBS per 
plate. Equal number of cells were counted for each condition and centrifuged at 
1,200 rpm for 10 min at R.T. to pellet the cells. After removal of PBS, 1 ml of R.T. 
1X PBS was added to gently resuspend the cells. 100μl of cell suspension was 
added in each PCR tube (Two groups total: compound treated and DMSO 
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treated. Each group had 10 tubes). Each tube was marked with a designated 
temperature. The tubes are kept at R.T. before the heat treatment step. 10 PCR 
tubes (2 samples per temperature: +/- PR5-LL-CM01) were heated with 
temperatures of 40, 43, 46, 49, 52, 55, 58, 61, 64, 67°C for 3 min in the 96-well 
thermal cycler. Immediately after heating, the tubes were incubated at R.T. for 3 
min, followed by immediately snap-freezing in liquid nitrogen. Cells were then 
lysed using alternate freeze thawing. The tubes were vortexed briefly after each 
thawing. The resulting cell lysates were then centrifuged at 10,000 rpm for 10 
min at 4°C to pellet cell debris together with precipitated and aggregated 
proteins. The respective supernatants with the soluble protein fraction were then 
run on a protein gel and were probed with anti-PRMT5 antibody using Western 
blotting technique described earlier. This helped to quantify PRMT5 expression in 
the cell lysates at different temperatures which was then plotted to obtain a 
melting curve. 
 
2.1.22 Generation of PR5-LL-CM01 Derivatives 
In collaboration with Dr. Lifan Zeng at IU Chemical Genomics Core, we 
generated a total of 20 derivatives of the parental compound PR5-LL-CM01. A 
detailed account of the synthesis process is included in Appendix B. 
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2.2 In Vivo Experiments 
2.2.1 Mice 
Male NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from the 
In Vivo Therapeutics Core (IVT) at Indiana University Melvin and Bren Simon 
Cancer Center. These mice are extremely immunodeficient strain and they lack 
mature T cells, B cells, and natural killer (NK) cells. Ideally, a mixture of male and 
female mice should be used and moving forward this will be our plan. Animals 
were housed in a pathogen-free environment and maintained on Teklad Lab 
Animal Diet (Harlan Laboratories). Access to sterile water and food was provided 
ad libitum under a 12 h light-dark cycle. The room temperature was maintained at 
22-24°C. All studies described here were performed in accordance with the 
guidelines and standards of the Institutional Animal Care and Use Committee 
(IACUC) and under the approved animal protocol #11066 by Indiana University. 
 
2.2.2 In Vivo Toxicity of PR5-LL-CM01  
This experiment was done in collaboration with the In Vivo Therapeutics 
Core at IUSM. After acclimation for 7 days, male NSG mice were injected with 
20mg/kg and 50mg/kg of PR5-LL-CM01 intraperitoneally (i.p.) 3X a week for 
week one and single injection daily for week two. Body weights were measured 
every 3 days and physical observations in gait and posture. were consistently 
monitored to identify any signs of toxicity. Additionally, paraffin-embedded 
samples of tumor, liver and, lung tissue from both the vehicle and PR5-LL-CM01-
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treated mice were stained with hematoxylin and eosin (H&E) to determine signs 
of tissue toxicity with the service of IUSM Histology Core.  
 
2.2.3 Subcutaneous Xenograft Model of PDAC and CRC 
Male NSG mice were obtained from the In Vivo Therapeutics Core at 
IUSM. After acclimation for 7 days, NSG mice (6-8 weeks old) were 
xenografted with Mycoplasma-free PANC1 or HT29 cells subcutaneously (s.c.) 
(1X107 PANC1 or 3X106 HT29 cells used per mouse) in 0.2 ml of a 1:1 mix of 
PBS and Matrigel (BD Biosciences). 5 mice were randomized in each group 
when tumor volumes reached ~100mm3. Mice were treated with either vehicle 
control or 20mg/kg of PR5-LL-CM01 (compound stock dissolved in 1:1 
Cremophor:ethanol solution) i.p. 3 times per week. Tumor volumes and body 
weights were measured twice a week using calipers and weighing scale 
respectively.  
 
2.2.4 Orthotopic Xenograft Model of PDAC  
NSG mice were injected with PANC-1 cells transduced with the lentiviral 
vector pCL6LucEGwo containing luciferase and green fluorescent protein cDNAs 
respectively as described previously (Shannon et al., 2015). The implant was 
done in collaboration with the In Vivo Therapeutics Core, with the cells injected 
directly in the pancreas. One week after implant, tumor growth was measured in 
collaboration with the Imaging core by injecting 150μg d-luciferin/mouse (Caliper 
Life Sciences) and visualized using the IVIS Imaging System. After the first 
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imaging session, mice were randomized based on the measured signal before by 
beginning the drug treatment every single day (SID) i.p. Imaging was then carried 
out every 7-14 days until the end of the study.  
 
2.2.5 Pharmacokinetic Study of PR5-LL-CM01 
This experiment was done in collaboration with the Clinical Pharmacology 
Analytical Core (CPAC) at IUSM. The method to quantify PR5-LL-CM01 in 
plasma was developed using liquid-liquid extraction (acetonitrile: 0.1% formic 
acid) and HPLC-MS/MS (ABSciex 5500 Q-TRAP). Acetaminophen was used as 
the internal standard. The mass spectrometer utilized an electrospray ionization 
probe run in positive mode.  The multiple reaction monitoring Q1/Q3 (m/z) 
transitions for PR5-LL-CM01 and acetaminophen are 402.1/357.3 and 
152.0/109.9, respectively.  The lower limit of quantification was 0.1 ng/mL using 
20μL of plasma. Variability was minimized in the method by using plastic tubes 
instead of glass tubes, and methyl tert-butyl ether instead of ethyl acetate, 
dichloroethane, or hexane:ethyl acetate. The mobile phase used formic acid 
instead of ammonium acetate. More details provided in Appendix C. 
 
2.3 Statistical analysis  
Statistical analysis for experiments mentioned in the entire Methods section 
was performed using Prism 6 software (GraphPad). The Z’ factor was 
calculated using the formula described in Zhang et al..: [Z’ = 1- {3 X SD positive 
control + 3 X SD negative control} / (mean positive control – mean negative 
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control}].  Percent inhibition for the compound library was calculated as follows: 
[({Avg. maximum reading – Inhibitor reading}/ Avg. maximum reading) X 100]. 
Results have been presented as mean ± SD or mean ± SEM, as specified. A 
two-tailed Student’s t test was used while comparing two means to test for 
significant differences for all other experiments. All statistics were calculated on 
triplicate experiments and p value < 0.05 was considered statistically 
significant.  
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CHAPTER 3. ASSESSING THE TUMOR PROMOTING ROLE OF PRMT5-
MEDIATED NF-kB IN PDAC AND CRC 
3.1 Background and Rationale 
PDAC and CRC are the leading causes of deaths in men and women 
combined in the United States. Besides having high mortality rates, the treatment 
options for both these cancers remain limited. Identification of new mechanisms 
underlying tumor promotion could open up new avenues for developing novel 
treatments that could not only increase survival but also improve the quality of life 
of these patients. 
 
An important common feature of both PDAC (Ling et al., 2012; Fujioka et 
al., 2003; Wang et al., 1999) and CRC (Mundade et al., 2014, Sakamoto et al., 
2009) is hyperactive NF-kB activity. NF-kB is a critical eukaryotic transcription 
factor whose family consists of five members: RelA (p65), RelB, cRel, NF-kB1 
(p50 and precursor p105), and NF-kB2 (p52 and precursor p100) (Ghosh et al., 
1988). The canonical pathway has been well established as a key contributor to 
development of both PDAC (Prabhu et al., 2014; Liou et al., 2013) and CRC 
(Agarwal et al., 2005; Yu et al., 2004). In this pathway, upon receiving 
extracellular signals such as pro-inflammatory cytokines. IkB kinase 
phosphorylates the inhibitor of kB (IkBα), leading to its degradation. This process 
results in the release of the p65:p50 complex, and the activation of NF-kB target 
genes (Gilmore 2006; Figure 3). A number of these downstream NF-kB target 
genes have been implicated in cancer. Increased NF-kB activation is not only 
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associated with poor disease prognosis, but also with developing resistance 
against chemotherapy in PDAC and CRC (Arora et al., 2013; Lind et al., 2001). 
Thus, controlling NF-kB activity is critical to the treatment of PDAC and CRC. 
 
Recently, our lab became the first to discover that protein arginine 
methyltransferase 5 (PRMT5) serves as a potent activator of NF-kB via 
dimethylating arginine 30 of its p65 subunit (Wei et al., 2013). Previous studies 
have implicated PRMT5’s role to promote cancer progression (Wei et al., 2013; 
Gu et al., 2012; Jansson et al., 2008), however its role via NF-kB-mediated 
activation in cancer has never been studied.  
 
The results depicted in this chapter provide the evidence that 
overexpression of PRMT5 correlated with promotion of several hallmarks of 
cancer including cell growth, anchorage-independent growth, and cell migration, 
at least partly via increased activation of NF-kB and activation of its downstream 
target genes, in both PDAC and CRC. Discovery of pathway-specific novel 
activators of NF-kB like PRMT5 can prove to be significant for drug target 
identification in PDAC and CRC treatment.  
 
3.2 Results 
3.2.1 PRMT5 is Overexpressed in PDAC and CRC Tissues 
Before examining the potential role of PRMT5 in PDAC and CRC, 
endogenous PRMT5 levels were checked in tumor tissue to see whether they 
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were elevated in these specimens versus normal tissue. Human tissue 
microarrays (TMAs) for PDAC and CRC were used, each containing an 
assembly of normal tissue and tissue from various stages of the respective 
cancers. TMAs were used as they allowed for a high throughput approach to 
analyze multiple specimens in a rapid, inexpensive and efficient manner. The 
TMA slides were first stained with hematoxylin and eosin, followed by probing 
with anti-PRMT5 antibody, in collaboration with Dr. George Sandusky at IUSM. 
Brown pigmentation was indicative of PRMT5 expression in the tissue. As shown 
in Figure 8, PRMT5 was significantly higher in various stages of PDAC, and 
particularly in metastatic stage, as compared to the normal PDAC adjacent 
tissue. Similarly, for CRC TMA, PRMT5 had much higher expression in samples 
ranging from inflammation, polyp, to the metastatic stage of CRC as compared 
to adjacent normal tissue. A particularly high PRMT5 expression seems to occur 
in Stage II CRC, which could be suggestive of this event being an early 
contributor to advance into higher stages of CRC. These data clearly 
demonstrated that PRMT5 is substantially overexpressed in both PDAC and 
CRC. 
 
3.2.2 PRMT5 is Overexpressed in PDAC and CRC Cells 
In order to determine whether PRMT5 has tumor promoting function in 
PDAC and CRC, we further examined PRMT5 expression in cell lines for both 
cancers by Western blotting. We chose AsPC1, MiaPaCa2 and PANC1 for PDAC 







Figure 8. PRMT5 is overexpressed in pancreatic and colorectal cancer 
tissue 
IHC staining, A (upper panel). showing that PRMT5 expression was higher in 
PDAC tumor tissues as compared to the normal tissue. B (upper panel). 
PRMT5 protein expression was higher in the inflammation, polyp, advanced 
stages of CRC and the metastatic stage as compared to the normal colon 
tissue. Quantification for IHC analysis of the PDAC and CRC tumor microarray 
(TMA). A (lower panel). Bar graph showing a significant increase in relative 
PRMT5 expression to normal tissue in primary stage tumor (n=19) and 
metastatic tumor patient tissue (n=6) vs. normal tissue (n=24) for the PDAC 
TMA. *p< 0.05, different samples vs. normal control. B (lower panel). IHC 
quantification of CRC TMA show a similar increase in relative PRMT5 
expression compared to normal cancer adjacent tissue for the representative 
disease stages in the TMA, including inflammation (n=9), polyp (n=5), benign 
tumors (n=5), primary tumors (n=14) and metastatic tissue (n=20) vs. normal 





Figure 9. PRMT5 is overexpressed in PDAC and CRC cells 
Western blots, A. showing that PRMT5 expression is higher in PDAC cells 
(AsPC1, MiaPaCa2 and PANC1) as compared to control pancreatic cells 
HPNE. B. PRMT5 expression is higher in CRC cells (HT29, HCT116 and 
DLD1) as compared to control colon cells FHC. b-actin was used as a loading 
control. 
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Both these sets of cell lines are well-established models in literature for the 
respective cancers (Ahmed et al., 2013; Deer et al., 2010). As shown in Figure 9A, 
PRMT5 was highly expressed in PDAC cells (AsPC1, MiaPaCa2 and PANC1) 
as compared to human normal pancreas HPNE cells. Similar experiments were 
carried out in a series of CRC cells (HT29, HCT116 and DLD1), with normal colon 
FHC cells as the control. Again, we observed that PRMT5 is highly expressed in 
CRC cells (Figure 9B). These data clearly demonstrated that PRMT5 is 
overexpressed in both PDAC and CRC cells. For further experiments, PANC1 and 
HT29 cells were chosen to generate the stable cell lines for PDAC and CRC 
respectively, since these are well-established cell line models, as described 
previously. 
 
3.2.3 Generation of Stable PRMT5 Overexpression and shRNA Knockdown Cell 
Lines 
Stable cells with either PRMT5 overexpression or shRNA knockdown 
were established in PANC1 (PDAC) and HT29 (CRC) cells by cloning Flag-
tagged WT-PRMT5 or shPRMT5 cDNA into pLVX-IRES-puro vector (Lu et al., 
2010). Here, we overexpressed PRMT5 further in cancer cells which already 
have high PRTM5 expression to show the significance of modulating a single 
factor such as PRMT5 and checking if it plays a critical role in that particular 
property just by its own overexpression. However, in the future, it would be more 
prudent to first knockdown endogenous PRMT5 and then overexpress the same.  
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After transfecting the respective lentiviral plasmids containing empty 
vector, WT-PRMT5 or shRNAs into a 293T packaging cell line, viral preps were 
generated to infect PANC1 or HT29 cells. 1μg/mL of puromycin was used for 
further selection, as the pLVX vector contains a puromycin resistance gene. For 
all the experiments described further in this section, the experiment was done 
using three biological replicates and pool of early passage infected stable cells 
that were frozen down at -80°C. Finally, Western blotting was conducted to 
confirm the expected PRMT5 expression. As shown in Figure 10, significant 
overexpression was observed in WT-PRMT5-PANC1 and WT-PRMT5-HT29 
respectively, as compared to the empty vector control. Conversely, shPRMT5-
PANC1 and shPRMT5-HT29 showed knockdown of PRMT5 in these cells, 
compared to the control. β-actin was used as a loading control. Upon confirmation 
of PRMT5 expression, we used these cell lines to pursue further assays that 
checked for various aspects of cancer phenotype in these cells. 
 
3.2.4 Overexpression of PRMT5 Promotes PANC1 and HT29 Cell Growth 
Cancer cells have a characteristic to proliferate much more rapidly than 
their normal counterparts (Hanahan and Weinberg 2011). In order to test if 
elevated levels of PRMT5 correlated with promoting the cell proliferating ability of 
PDAC and CRC cells, cells were seeded in 6-well plates and checked for growth 
over a period of 9 days, by staining with crystal violet. These stained cells were 




Figure 10. Generation of stable PRMT5 overexpression and shRNA 
knockdown cell lines 
Western blot, confirming stable PRMT5 overexpression and shPRMT5 
knockdown in A. PANC1 and B. HT29 cells. β-actin was used as a loading 
control. 
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We show that overexpression of PRMT5 promoted cell growth, while  
shRNA knockdown reduced this effect in both PDAC and CRC cells starting at 
day 5 (Figure 11) as compared to the control cells. This data confirmed that 
PRMT5 played an important role in promoting cell proliferation in these cells.  
 
3.2.5 Overexpression of PRMT5 Promotes Migration of PANC1 and HT29 Cells 
Another well-known property of cancer cells is their ability to migrate, which 
is critical for invasion and metastases by these tumors (Shaw 2005). Different 
methods have been used to quantify cell migration levels, including scratch-
wound assays, cell-exclusion zone assays and Boyden Chamber assays. The 
Boyden Chamber assay is a widely accepted technique for studying cell migration 
and contains a plastic chamber with a porous membrane at its bottom. Inside this 
chamber are cells that are suspended in media with low serum, creating nutrient-
starved conditions. Outside the chamber is medium containing high serum, 
replicating nutrient-rich conditions. Cells placed inside the chamber tend to 
migrate through the pores, from the area of low nutrient to high nutrients. The 






Figure 11. Overexpression of PRMT5 promotes PANC1 and HT29 cell 
growth 
Cell proliferation assay, showing that cell proliferation was significantly higher 
in the WT-PRMT5 cell lines, while shPRMT5 cells exhibited quite opposite 
effect compared to empty vector Ctrl in both A. PANC1 and B. HT29 cells. *P < 




Figure 12. Overexpression of PRMT5 promotes migration of PANC1 and 
HT29 cells. 
Cell migration assay, showing that cell migration was significantly higher in the 
WT-PRMT5 overexpression cells, while significantly reduced in the shPRMT5 
cells. Upper panels, representative pictures in 20X magnification. Lower panel, 




Figure 13. Overexpression of PRMT5 promotes colony independent 
growth of PANC1 and HT29 cells 
Anchorage-independent growth was significantly higher in the WT-PRMT5 cell 
lines, while dramatically reduced in the shPRMT5 cells in A. PANC1 and B. 
HT29 cells. Both colony size and number are quantified at the bottom of the 
corresponding panels. *P < 0.05 vs. Ctrl group. 
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As observed in Figure 12, overexpression of PRMT5 increased the 
number of migrated cells (in purple), whereas shPRMT5 knockdown showed 
quite opposite effect. Representative pictures for each condition were taken in 
20X magnification. Overall, these results indicate that PRMT5 enhanced the 
migratory ability of both PDAC and CRC cells.  
 
3.2.6 Overexpression of PRMT5 Promotes Anchorage-Independent Growth of 
PANC1 and HT29 Cells 
The ability to grow independently of a solid surface is a hallmark of cancer 
cells. In order to test if PRMT5 can affect this property, we conducted an 
anchorage-independent growth assay in soft agar (Borowicz et al., 2014). Data 
suggested that PRMT5 overexpression led to a dramatic increase in both the 
colony size and number in PANC1 and HT29 cells (Figure 13), while shPRMT5 
knockdown significantly reduced this ability, confirming the critical role that 
PRMT5 plays in promoting anchorage-independent cell growth in PDAC and 
CRC. 
 
Overall, PRMT5 promoted several characteristics associated with cancer 
cells, including increased proliferation, migration and anchorage-independent 
growth. Next, we wanted to check how PRMT5 overexpression correlated with 
activation of its substrate NF-kB. 
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3.2.7 Overexpression of PRMT5 Activates NF-kB in PDAC and CRC Cells 
Previously, we discovered that PRMT5 activates NF-kB through 
methylation of its p65 subunit in HEK293 cells (Wei et al., 2013). This is a 
significant finding, as NF-kB has been shown to be constitutively activated in 
multiple cancers and is a well-established tumor promoting factor. However, it is 
also important for normal functioning of cells. Thus, direct targeting may not always 
be feasible. Discovery of factors like PRMT5 is significant, as it could allow for 
indirect targeting of NF-kB and thereby providing a viable therapeutic option. 
 
In this regard, it was worth determining the impact of PRMT5 on NF-kB 
activation. NF-kB activity was measured using transient transfection of the 
construct p5XIP10 (containing five tandem copies of the NF-kB site from the 
IP10 gene upstream of the luciferase reporter gene) and addition of luciferase 
substrate 48 h after transfection. If PRMT5 affected NF-kB activation, then we 
would see increased binding of the active p65 subunit of NF-kB to its consensus 
site of the IP10 gene, leading to increased transcription and translation of the 
downstream luciferase reporter gene. Upon addition of luciferase substrate, a 
fluorescent product is formed by the luciferase enzyme which is directly 
proportional to the level of NF-kB activity in the cells, thus allowing to assay its 
activity. 
 
As illustrated in Figure 14, overexpression of PRMT5 significantly 
enhanced NF-kB activity, while shPRMT5 knockdown exhibited a quite opposite  
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Figure 14. Overexpression of PRMT5 activates NF-kB in PDAC and CRC 
cells 
NF-kB luciferase assay, showing that overexpression of WT-PRMT5 led to NF-
kB activation, while shPRMT5 resulted in quite opposite effect in A. PANC1 
and B. HT29 cells. *P < 0.05 vs. Ctrl.  
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effect, as compared to the control cells, indicating that PRMT5 indeed 
significantly activated NF-kB in both PDAC and CRC cells. 
 
3.2.8 Overexpression of PRMT5 Induces the Expression of NF-kB Target Genes 
in PDAC and CRC Cells 
 
Our lab previously showed that PRMT5-mediated NF-kB activation led 
to the induction of typical NF-kB target genes, such TNFa and IL8 in 293 cells 
(Wei et al., 2013). Thus, in order to understand the effect of PRMT5 
overexpression on the upregulation of these genes in PDAC and CRC cells,  
we performed quantitative PCR showed that upon stimulation with IL-1b, there 
was a substantial increase in the expression of TNFa and IL8 in PRMT5  
overexpressing cells, while a dramatic reduction was observed upon shPRMT5 
knockdown, in both PANC1 and CRC cells, indicating that activation of NF-kB by 
PRMT5 led to a further activation of known NF-kB-dependent downstream target 
genes TNFa and IL8 (Figure 15). Both these genes are highly expressed and 
critical players in the tumor microenvironment and disease progression (Mager et 
al, 2016; Błogowski et al., 2014). More importantly, TNFa and IL8 were shown to 
be amongst the most highly upregulated genes in terms of their mRNA 
expression in a tissue microarray that compared PRMT5 overexpressed cells to 
vector control cells in a 293 background (Wei et al., 2013). Other downstream 
NF-kB target genes may be affected that play a critical role in promoting different 





Figure 15. Overexpression of PRMT5 induces the expression of NF-kB 
target genes in PDAC and CRC cells 
qPCR analysis, showing that overexpression of PRMT5 significantly enhanced 
IL-1β-triggered NF-kB target genes (TNFα and IL8) expression, while 
shPRMT5 exhibited quite opposite effect, in both A. PANC1 and B. HT29 cells. 
*P < 0.05 vs. Ctrl; #P < 0.05 vs. Ctrl+IL-1β-treated group. 
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those in the future. Thus, PRMT5 could have tumor-promoting function by 
upregulating NF-kB-directed activation of downstream target genes that are 
critical in the advancement of the disease phenotype. 
 
3.3 Concluding Remarks 
Here, we provide the first link for a PRMT5-mediated NF-kB signaling 
pathway in PDAC and CRC. Our findings show that PRMT5 promotes cell 
proliferation, migration and anchorage-independent growth, which are critical 
hallmarks of cancer. More importantly, overexpression of PRMT5 was capable of 
promoting NF-kB activation itself as well as activation of downstream target 
genes. This underlies the significance of a novel signaling mechanism 
responsible for NF-kB activation in PDAC and CRC. These findings also opened 
up the exciting possibility of PRMT5 having therapeutic relevance. Inhibiting 
PRMT5 activity could serve as a means to indirectly control constitutive NF-kB 
activation observed in PDAC and CRC, thereby leading to a possible alleviation 
of the cancer phenotype. In the next two chapters, we explore the therapeutic 
relevance of developing specific PRMT5 inhibitors in PDAC and CRC. 
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CHAPTER 4. DISCOVERY OF PR5-LL-CM01 AS A NOVEL PRMT5 SMALL-
MOLECULE INHIBITOR FROM HIGH THROUGHPUT SCREEN #1 
4.1 Background and Rationale 
PRMT5, a member of PRMT superfamily, can contribute to cancer 
promotion, making it a potential target for cancer therapy. In Chapter 3, we 
highlighted the potential role of PRMT5 as a tumor promoting factor, at least partly 
via NF-kB activation. In this regard, we hypothesized that inhibition of PRMT5 
with small-molecule inhibitors could have potential therapeutic implications in 
PDAC and CRC.   
 
In this study, we developed a highly sensitive (Z’ score = 0.6) robotic high 
throughput screen (HTS) platform by adapting the AlphaLISATM technology to 
discover small molecule inhibitors of PRMT5. This assay could precisely quantify 
PRMT5 methylation of its substrate in a 384-well HTS platform. Compared to the 
conventional methods such as time resolved fluorescence energy transfer (TR-
FRET) assay, the AlphaLISA technology is proved to be more sensitive, reliable, 
and adaptable for performing large-scale reactions. Thus, it proves to be a 
more robust assay to be used for screening as compared to other methods 
used in the past (Simard et al., 2013, Quinn et al., 2010). Additionally, 
PerkinElmer had highly specific reagents for our purpose, such as beads with 
antibodies highly specific for the dimethyl tag introduced by PRMT5 on its 
substrate. To date, AlphaLISA has never been used for screening of PRMT5 
inhibitors in the HTS format. In collaboration with the IU Chemical Genomics 
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Core, we successfully modified this technique from bench scale to a condition 
that can provide robust results in a robotic system. Briefly, PRMT5 transferred 
the methyl groups from its methyl donor SAM to biotin-histone H4 peptide (a 
well-known PRMT5 substrate), leading to its symmetric dimethylation, which was 
recognized by the Acceptor beads conjugated with the anti-H4R3me2 
antibody and the streptavidin tagged Donor beads. Upon excitation with light, 
emitted signal was detected by an EnVision® Reader, which was proportional to 
the amount of dimethylated H4R3 (Figure 16). Therefore, for any small-molecule 
inhibitor used to inhibit the activity of PRMT5, a reduced signal emission would 
be detected. Using this powerful approach, we identified a selective PRMT5 
inhibitor PR5-LL-CM01, and further validated their efficacy and selectivity for 
inhibiting PRMT5. Importantly, it exhibited much more efficacy than the commercial 
PRMT5 inhibitor EPZ015666 in both PDAC and CRC cells. Overall, our work 
highlights a novel, powerful, and sensitive approach to identify specific PRMT5 
inhibitors.  
 
This chapter provides a detailed account of the development and 
optimization of the AlphaLISA protocol for an HTS to screen for small-molecule 
inhibitors of PRMT5, identification of PR5-LL-CM01 as a novel PRMT5 inhibitor, 
and the subsequent validation of its specificity and efficacy in both in vitro and in 




Figure 16. Schematic Illustration of the AlphaLISA Technique 
Biotinylated histone H4 is incubated with PRMT5 and methyl donor SAM. 
PRMT5 symmetrically dimethylated H4 on its arginine 3, a product that is 
recognized by Acceptor beads. Following the binding of Donor beads, the 
chemiluminescent signal is emitted and detected by the EnVision® Reader. The 
intensity of the Alpha signal is proportional to the PRMT5 activity. 
73 
4.2 Results 
4.2.1 Development and Optimization of PRMT5-Specific AlphaLISA HTS Assay 
The first step in developing an HTS for PRMT5 inhibitors was to design an 
assay that could accurately measure PRMT5 methyltransferase activity and was 
adaptable to a large-scale screening platform, such that reduction in enzyme 
activity in presence of inhibitors could be quantified. For this purpose, we utilized 
the AlphaLISA assay as per the principle described in Figure 16.   
 
AlphaLISA protocol requires several critical components, including 
substrate H4R3, the methyl donor SAM, PRMT5 enzyme as well as Acceptor and 
Donor beads (Table 1). We purified PRMT5 enzyme using co-
immunoprecipitation experiments with Flag beads from 293-PRMT5-Flag cells. 
293-PRMT5-Flag cells have overexpressed Flag-tagged PRMT5 (Figure 17) and 
allow for efficient purification of PRMT5. The manufacturer-recommended 
dilutions for the Acceptor as well as the Donor beads helped us to obtain the 
desired signal. The major optimization was necessary for the unmethylated H4R3 
substrate (unmeH4R3) and SAM concentrations to be used in the experiment. 
First, we optimized the substrate concentration by running the AlphaLISA assay 
with 10-100nM final concentration of the unmeH4R3 substrate in the reaction 
well. We observed that with increasing concentrations of substrate, there was a 
predictable increase in the AlphaLISA signal (Figure 18A). Since using the lower 
concentrations provided a robust signal in the pilot experiment, we decided to 
use 30nM of unmeH4R3 as our final condition.  
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Figure 17. PRMT5 was Overexpressed in the 293-WT-PRMT5-Flag Cells 
Western blot, showing that Flag-tagged WT-PRMT5 was overexpressed in the 
293-WT-PRMT5-Flag cells as compared to the control 293 line. The 293-WT-
PRMT5-Flag cell line was used to purify PRMT5 enzyme for the AlphaLISA 
assay, using co-immunoprecipitation with anti-Flag beads. 
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Figure 18. Optimization of the AlphaLISA Protocol 
A. Alpha signal graph, showing that the Alpha signal increased with increased 
substrate (unmeH4R3) concentrations (10-100nM). B. Alpha signal graph, 
showing that increased concentrations of the methyl donor SAM (0.2-4000mM) 
led to a bell-shaped distribution of Alpha signal strength. We observed an 
increase in the Alpha signal, with a peak at 100mM of SAM, followed by a 
subsequent decrease with further increased SAM concentrations. 
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Next, with the aim to maximize the AlphaLISA signal, we determined if a 
specific concentration of the methyl donor SAM worked best in this assay. We 
tested a wide range of SAM concentrations (0.2μM to 2000μM) while keeping all 
the other components same, including the substrate concentration at 30nM as 
described above. We observed a steady increase in AlphaLISA signal, with a 
peak at 100μM SAM, that decreased at higher concentrations (Figure 18B). 
Thus, we decided to choose a final concentration of 100μM SAM in our HTS 
assay.  These assays also allowed us to adjust and test volumes and 
concentrations that were permissible for the robotic approach, thus helping us to 
automate the addition of these reagents in the actual HTS. 
 
4.2.2 Conduction of the Z’ Experiment to Test the Sensitivity of the PRMT5-
specific AlphaLISA HTS Technology   
After successfully determining the important parameters for assay 
development, we executed the Z’ test to check the robustness of the assay.  
Calculation of the Z’ factor allows for evaluation and validation of HTS assays 
(Zhang et al., 1999), as it allows to assess the range of signal generated in the 
assay as well as accounts for variation associated with the signal measurements. 
We used a 384-well white opaque plate to run the Z’ test. Briefly, half of the plate 
was used as “maximum signal” wells (with the PRMT5 enzyme added) and the 
other half was used as “background wells” (with no PRMT5 enzyme, only assay 
buffer added) (Figure 19A). We used a 20µl reaction volume as described in 
Table 1. The graph for Z’ factor determination is illustrated in Figure 19B. An  
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Figure 19.  Z’ Assay Design 
A. Plate design to calculate the Z’ ratio. B. Z’-plot of AlphaLISA assay, showing 
that Alpha signal with PRMT5 (red dots) is significantly higher than those without 
PRMT5 (blue dots). The mean values are represented with solid horizontal lines 
in the center of each sample group. Z’ value for our experiment was 0.6. 
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assay with a Z’ value > 0.5 is widely considered to be sensitive enough for a 
successful HTS. The Z’ factor was calculated to be 0.6 and a 
signal/background ratio of ~7. This test confirmed that our adapted PRMT5-
specific AlphaLISA HTS technique was sensitive, robust, and successful. Once 
the assay was proven HTS-compatible, the next step was to scale it up to run a 
HTS screen using large-scale small compound libraries. 
 
4.2.3 Using PRMT5-Specific AlphaLISA HTS to Identify a Novel Small-Molecule 
Inhibitor of PRMT5: PR5-LL-CM01 
Using PRMT5-specific AlphaLISA HTS technique, we successfully 
screened a library with 10,000 small molecules purchased from ChemDiv Inc. A 
representative 384-well plate in the HTS (Figure 20) shows a potential hit 
highlighted in red, with a significant decrease observed in the AlphaLISA signal, 
as compared to that with no inhibitor.  
 
Several top hits were identified and confirmed using both AlphaLISA and 
MTT assay in PDAC and CRC cells. Among these, the leading compound was 
PR5-LL-CM01. PR5-LL-CM01 consists of a pyrozolo-pyrimidine core and three 





























































































































































































Figure 21. Structure of PR5-LL-CM01 
The core structure of a pyrozolo-pyrimidine group is highlighted in a red box and 
three surrounding groups A, B and C, respectively with colored circles in the 
structure of PR5-LL-CM01. This structure is part of the patent filed under 




4.2.4 Confirmation of PRMT5 Inhibition Effect of PR5-LL-CM01 by AlphaLISA 
Technique 
In order to confirm the effect of the inhibitor on PRMT5, we used the 
AlphaLISA approach with increasing concentrations of PR5-LL-CM01 to determine 
its effect on PRTM5 methyltransferase activity. We would expect a concentration-
dependent decrease in PRMT5 activity with increasing concentrations of PR5-
LLCM01 if it was specific for inhibiting PRMT5 methyltransferase activity. We saw 
the expected concentration dependent effect with PR5-LL-CM01 and confirmed 
that the IC50 of PR5-LL-CM01 was 7.5μM by the AlphaLISA approach (Figure 22). 
Here, we have not excluded if the inhibitor just inhibits the Ab binding or the 
biotin:streptavidin reaction to show decrease in Alpha signal that we observe. With 
the fact that the binding affinity of biotin-avidin and the Ab-methyl group reaction 
is quite high, the inhibitor interfering with those reactions is highly unlikely. More 
specific controls can be included in the future. 
 
4.2.5 MTT Assay to Determine IC50 in PDAC and CRC Cells 
In order to determine the efficacy of PR5-LL-CM01, we used both PDAC 
and CRC cells as the in vitro models. These are the same set of cancer cell lines 
used in Chapter 3 to check for PRMT5 expression (Figure 9). Both PDAC and 
CRC cells were treated with increasing concentrations of PR5-LL-CM01 and 
quantified for cell viability with the MTT assay. We showed that PR5-LL-CM01 had 
a range of IC50 at 2-4µM in PDAC cells (PANC1, MiaPaCa2 and AsPC1) 





Figure 22. PR5-LL-CM01 shows a Concentration-Dependent Decrease in 
Methyltransferase Activity. 
Using AlphaLISA, increasing concentrations of PR5-LL-CM01 showed a relative 
decrease in Alpha signal, indicative of decrease in methyltransferase activity of 
PrMT5. The IC50 was ~7.5μM. 
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Figure 23. PR5-LL-CM01 is a Potent Inhibitor of PRMT5 in PDAC and CRC 
Cells 
A. MTT assay in PDAC cells (PANC1, MiaPaCa2 and AsPC1), showing that cell 
viability decreased significantly in presence of increasing concentrations of PR5-
LL-CM01. B. MTT assay in CRC cells (HT29, HCT116, and DLD1), showing 
dramatic decrease of cell viability in presence of increased concentrations of 
PR5-LL-CM01. C. Table, summarizing the IC50 values for PR5-LL-CM01 in 
PDAC and CRC cells, respectively. 
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HCT116 and DLD1) (Figures 23B and C). Overall, the IC50 of PR5-LL-CM01 was 
in the low µM range for both sets of cell lines. 
 
Recently, Chan-Penebre et al. identified a PRMT5 inhibitor, EPZ015666 
and showed its high efficacy in inhibiting PRMT5 in mantle cell lymphoma 
disease models. We wanted to understand whether EPZ015666 would be 
effective in PDAC and CRC. Since this compound is commercially available, we 
tested it in our PDAC and CRC cell lines. Our data suggested that EPZ015666 
was much less effective as compared to PR5-LL-CM01, with a range of IC50 at 
50-95μM for PDAC cells, and a range of IC50 at 180-195μM for CRC cells 
(Figure 24). Therefore, our data suggested that PR5-LL-CM01 is a more potent 
PRMT5 inhibitor than EPZ015666 in PDAC and CRC cells. 
 
4.2.6 PR5-LL-CM01 Inhibits Anchorage-Independent Growth of PDAC and CRC 
Cells 
Next, we used the anchorage-independent assay described previously to 
check if treatment with PR5-LL-CM01 affected colony formation of either 
PDAC or CRC cells. We observed that treatment with PR5-LL-CM01 at 
increasing concentrations strongly inhibited colony forming ability in both PANC1 
and HT29 cells (Figure 25). This indicates that PR5-LL-CM01 successfully 






Figure 24. Effect of EPZ015666 on PDAC and CRC Lines 
A. MTT assay, showing that in PDAC cells (PANC1, MiaPaCa2 and AsPC1) 
EPZ015666 decreased cell viability, however had a lower efficacy to decrease 
cell viability than that of PR5-LL-CM01. B. MTT assay, showing that in CRC cells 
(HT29, HCT116, and DLD1), EPZ015666 decreased cell viability, but had lower 
efficacy to decrease cell viability than that of PR5-LL-CM01. The data represent 
the means ± S.D. for three independent experiments. *P < 0.05 vs. Ctrl group. C. 
Table summarizing the IC50 values for EPZ015666 in PDAC and CRC cell lines. 
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Figure 25. Effect of PR5-LL-CM01 on Anchorage-Independent Growth of 
PDAC and CRC Lines 
Anchorage-independent assay, showing that with increasing concentrations of 
PR5-LL-CM01, there was a significant decrease in the anchorage-independent 







Figure 26. Effect of PR5-LL-CM01 3D Colony Formation of PDAC and CRC 
Lines 
3D colony formation assay, showing that with increasing concentrations of PR5-
LL-CM01, there was a significant decrease in the 3D colony formation ability in 
both PANC1 as well as HT29 cells. A. Representative pictures in 4X 
magnification. B. Quantification for the fold change in 3D colony formation, upon 
treatment with increasing concentrations of PR5-LL-CM01, as compared to the 
untreated control. 
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4.2.7 PR5-LL-CM01 Inhibits 3D Culture Growth of PDAC and CRC Cells 
In light of recent work suggesting 3D spheroidal cell culture may closely 
mimic the in vivo tumor microenvironment such as having a hypoxic core, 
decreased spheroid- spheroid contact and greater survival (Fennema et al., 
2014; Heylman et al., 2014), we determined the efficacy of PR5-LL-CM01 
against 3D spheroids of PDAC and CRC cells. As shown in Figure 26, with 
increasing concentrations of PR5-LL-CM01, we observed a dosage-dependent 
decrease in the ability of both PANC1 and HT29 cells to form 3D spheroids in 
culture, highlighting the tumor-inhibiting potential of PR5-LL-CM01 in vitro. 
 
4.2.8 PR5-LL-CM01 Inhibits NF-kB Symmetric Dimethylation and Downstream 
Activation 
Previously we found that PRMT5 activated NF-kB through methylation of 
its p65 subunit (Wei et al., 2013). Therefore, we would expect that treatment with 
a specific PRMT5 inhibitor, PR5-LL-CM01 would reduce NF-kB methylation and 
subsequent activation. Accordingly, we first tested the effect of PR5-LL-CM01 on 
the symmetric dimethylation status of p65, the active subunit of NF-kB. 293 cells 
engineered to overexpress Flag-p65 were treated with 20μM PR5-LL-CM01 for 
24h. Flag-p65 was pulled down with anti-Flag-M2 beads and further analyzed 
with Western blot by probing with anti-dimethylated arginine antibody (Figure 
27). We show that, compared to the untreated control cells, treatment with PR5-




Figure 27. PR5-LL-CM01 Inhibits NF-kB Symmetric Dimethylation Status 
Co-IP-Western blot, showing that treatment with 20μM PR5-LL-CM01 inhibited 
p65 methylation, a PRMT5 substrate, in 293-WT-p65-Flag cells. Flag beads 
were used to pull down WT-p65-Flag and samples were probed with anti-






Figure 28. PR5-LL-CM01 Inhibits NF-kB Activity in PDAC and CRC Cells 
Luciferase assay, showing a decrease in NF-kB activation with increasing 
concentrations of PR5-LL-CM01 in PANC1 (upper panel) and HT29 cells 
(lower panel). A much higher concentration of EPZ015666 is needed in order 
to reach similar level of NF-kB inhibition as that of PR5-LL-CM01. The data 
represent the mean ± S.D. for three independent experiments. *P < 0.05 vs. 
Vehicle group (0µM). 
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confirmed that PR5-LL-CM01 inhibited PRMT5-specific methyltransferase activity 
in vitro. 
 
In order to further examine if PR5-LL-CM01-mediated inhibition of PRMT5 
affected subsequent activation of NF-kB, we conducted a luciferase assay as 
described previously. As shown in Figure 28, treatment with increasing 
concentrations of PR5-LL-CM01 resulted in a corresponding decrease in NF-
kB activation in PANC1 and HT29 cells. Alongside PR5-LL-CM01, we also 
tested how efficacious EPZ015666 was in reducing NF-kB activation (Figure 
28). These data demonstrate that PR5-LL-CM01 was significantly more potent in 
decreasing NF-kB in PDAC and CRC cells than the commercially available 
PRMT5 inhibitor, EPZ015666.  
 
We further tested if a decrease in NF-kB activation observed above 
resulted in a corresponding decrease in the induction of NF-kB target genes that 
are critical in promoting the hallmarks of cancer. We observed that treatment 
with PR5-LL-CM01 led to a significant decrease in both NF-kB target genes, IL8 
and TNFa (Figure 29), indicating that PR5-LL-CM01 significantly decreased 
PRMT5-mediated NF-kB-dependent gene activation. Overall, we observed that 
PR5-LL-CM01 had significant efficacy in inhibiting NF-kB methylation, its 






Figure 29. PR5-LL-CM01 Inhibits the Expression of NF-kB Target Genes in 
PDAC and CRC Cells 
qPCR analysis, showing that treatment with PR5-LL-CM01 dramatically 
decreased TNFα and IL8 expression, in both PANC1 and HT29 cells. The data 







Figure 30. PR5-LL-IEC01, a Structural Analog of PR5-LL-CM01 
A. Structure of PR5-LL-IEC01, in side-by-side comparison to the lead 
compound, PR5-LL-CM01. B. Calculation of IC50 of PR5-LL-IEC01 using 
AlphaLISA, with IC50 calculated to be ~118μM, several fold higher than the lead 
compound PR5-LL-CM01. 
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4.2.9 Selectivity of PRMT5 Inhibition Effect of PR5-LL-CM01  
In order to check the specificity of PR5-LL-CM01 to PRMT5, we generated 
PR5-LL-IEC01, a structural analog of PR5-LL-CM01 (Figure 30A). Multiple 
analogs, including PR5-LL-IEC01 were generated for the SAR analysis that 
has been described later in Section 4.2.17. We tested all of them versus the 
parental compound. PR5-LL-IEC01. This particular analog, PR5-LL-IEC01 was 
chosen to be used as a representative compound here based on the fact that 
this analog had amongst the very least difference in its structure from the 
parental compound as demonstrated in Figure 30 and thus was chosen for the  
purpose of this study. The IC50 of PR5-LL-IEC01 was calculated to be 118μM by 
AlphaLISA (Figure 30B), about 16-fold higher than that of PR5-LL-CM01 
(Figure 22), affirming that the inhibition of PRMT5 methyltransferase activity 
observed by AlphaLISA assay was specific to small-molecule inhibitor PR5-LL-
CM01.  
 
Furthermore, we examined the inhibition by PR5-LL-CM01 against 
other PRMT family members using the HotSpot radioisotope-based platform 
(Reaction Biology Corp) (Horiuchi et al., 2013), as described in Section 2.1.18. 
This assay allows for detection of the levels of SAM being turned over in the 
reaction by loss of its methyl group, thereby enabling quantification of the 
respective enzyme activity. As shown in Figure 31, these PRMTs showed zero 
effect, or at least a 10-fold higher IC50 than that of PRMT5, indicating the high 
selectivity of PR5-LL-CM01 for PRMT5 over its other family members. 
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Figure 31. Selectivity of Inhibition by PR5-LL-CM01 against the Enzymatic 
Activity of Protein Arginine Methyltransferase Family Members 
The specificity of inhibition was analyzed using the HotSpot radioisotope-based 
platform (Reaction Biology Corp). PR5-LL-CM01 showed high specificity to 
PRMT5, while showed either zero effect or at least a 10-fold higher IC50 to other 
PRMT family members than that of PRMT5.  1-fold means no difference as it is 
compared to PRMT5.  
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% survival in control cells  
(treated with IC50 of 
respective cancer cell line) 
PDAC 
Normal control: HPNE 
PANC1 4 80% 
MiaPaCa2 2 90% 
AsPC1 4 80% 
CRC 
normal control: FHC 
HT29 10 80% 
HCT116 10 80% 




Figure 32. Effect of PR5-LL-IEC01 on Cell Viability of PDAC and CRC 
Lines 
A. MTT assay in PDAC (PANC1) and CRC (HT29), showing a high IC50 for PR5-
LL-IEC01 in both the cell lines. B. Table, summarizing the IC50 values for PR5-






Figure 33. Treatment with PR5-LL-IEC01 had No Effect on NF-kB 
Activation in PDAC and CRC Cells 
NF-kB luciferase assay, showing that upon treatment with increasing 
concentrations of structural analog PR5-LL-IEC01, there was no change in NF-
kB activation in PANC1 and HT29 cells. 
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Additionally, as compared to cancer cell lines, the respective normal 
control cells had a much higher survival at the IC50 observed in their cancer cell 
line counterparts (Table 2). HPNE and FHC are the normal pancreatic and colon 
control cell lines respectively, that were used in the present study. This 
suggested that PR5- LL-CM01 had was more efficacious in specifically inhibiting 
Additionally, as compared to cancer cell lines, the respective normal control cells 
had a much higher survival at the IC50 observed in their cancer cell line 
counterparts (Table 2). HPNE and FHC are the normal pancreatic and colon 
control cell lines respectively, that were used in the present study. This cancer 
cells compared to normal cells from the same tissue of origin. In addition, we 
determined the IC50 of the inactive structural analog PR5-LL-IEC01 in PANC1 and 
HT29 cells using the MTT assay.  Not surprisingly, the potency of PRC-LL-IEC01 
was considerably less with an IC50 >14-40 fold compared to PR5-LL-CM01 
(Figure 32) in the same cell lines. Moreover, when we checked for NF-kB 
activation upon treatment with inactive analog, PR5-LL-IEC01 had no significant 
effect on the NF-kB activation in both PDAC and CRC cells, indicating the 
specificity of PR5-LL-CM01 to decrease NF-kB activation in these cell lines 
(Figure 33). Overall, these data support the specificity of PRMT5 inhibition effect 




4.2.10 Structural Prediction of PR5-LL-CM01 Docked to PRMT5 
With all the studies described so far, it is clear that PR5-LL-CM01 is 
specific for PRMT5 and is efficacious in reducing the cancer phenotype in PDAC 
and CRC cells. In order to delve deeper into the possible interactions between 
PR5-LL-CM01 and PRMT5, we employed a structural modeling approach using 
the existing information of PRMT5 crystal structure (Antonysamy et al., 2012). 
This work was in collaboration with Dr. Ozlem Demir at the University of 
California, San Diego under the guidance of Dr. Rommie Amaro. In addition to 
PR5-LL-CM01, we also included EPZ015666 in the analysis to determine if there 
were any similarities between the two inhibitors in their respective interactions 
with PRMT5. As illustrated in Figure 34, PR5-LL-CM01 was docked in the 
presence (SAM-bound) or absence of SAM (Apo-PRMT5). Under SAM-bound 
condition (Figure 34, upper left panel), the binding sites for PR5-LL-CM01 
and EPZ015666 on PRMT5 overlap to a great extent, indicating that these two 
inhibitors probably interact with PRMT5 through largely similar group of binding 
sites. However, in the Apo-PRMT5 condition, though the binding sites of 
EPZ015666 remain the same as those in SAM-bound condition, the binding 
position of PR5-LL-CM01 shifted dramatically from its original binding position in 
the SAM-bound condition to the new position (pink dotted line, Figure 34 upper 
right panel), which is similar as the SAM binding position in the SAM-bound 
condition (Figure 34, upper left panel). This interesting phenomenon 
suggested that PR5-LL-CM01 could interfere with the residues involved in SAM 
binding to PRMT5 in SAM-bound PRMT5, but  might also block the binding of 
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SAM to Apo-PRMT5 by occupying the similar binding site for SAM. In 
contrast, EPZ015666 binding stayed the same in both SAM-bound or Apo-
PRMT5 conditions, thus binding to PRMT5 in a completely independent manner 
from SAM, which is consistent with previously published data (Chan-Penebre 
et al., 2016). In addition, we showed that both binding events under SAM-bound 
or Apo-SAM conditions are energetically beneficial, with the Apo-PRMT5 (-
7.911 kcal/mol) being slightly more favorable than the SAM-bound condition (-
6.949 kcal/mol) (Figure 34, lower panel).  
 
A ligand binding affinity map (Figure 35A) further depicts the PRMT5 
residues that interact with PR5-LL-CM01 in the SAM-bound condition. 
Importantly, PR5-LL-CM01 forms a hydrogen bond with the E444 residue in 
the PRMT5 active pocket. This residue is essential for the methyltransferase 
activity of PRMT5. There is also another critical interaction observed with F327, 
which is a residue that is important for determining the symmetric dimethylation 
activity of PRMT5 vs. other PRMTs, which display asymmetric dimethylation or 
monomethylation. Both these interactions hint at yet another layer of mechanistic 





Figure 34. In Silico Prediction of PR5-LL-CM01 and EPZ015666 
respectively Binding to PRMT5 
Upper left panel, In SAM (purple color)-bound condition, the binding sites for 
PR5-LL-CM01 (turquoise color) and EPZ015666 (orange color) on PRMT5 
overlap to a great extent, suggesting that these two compounds inhibit 
PRMT5 through largely similar group of binding sites. Upper right panel, in 
Apo-PRMT5 condition, the binding of EPZ015666 remains the same as that in 
the left panel, however, PR5-LL-CM01 has shifted dramatically from its left 
panel’s position (red dotted line) to the new position (pink dotted line), which is 
same as SAM’s position in the left panel.  Lower panel, Table, listing the 
binding affinities of  PR5-LL-CM01-PRMT5 interactions in SAM bound and 
Apo-PRMT5 conditions. PR5-LL-CM01 showed favorable binding energies 
under both conditions, with Apo-PRMT5 condition having a slightly stronger 
binding affinity (-7.911 kcal/mol).  
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Since under the SAM-bound condition, PR5-LL-CM01 and EPZ015666 
bind to PRMT5 in a largely overlapped region (Figure 34), we looked at these 
residues in much more detail in Figure 35B. The sites that can solely interact 
with PRMT5 by PR5-LL-CM01 are denoted in red, solely by EPZ015666 in blue, 
or by both in green. Most of the residues are present in the Rossman fold, 
followed by several residues in the b-barrel, and some residues in the linker 
domain of the PRMT5 structure (Figure 6). Since the methyltransferase domain 
is comprised within the Rossman and b-barrel domains, these evidences 
further support that PR5-LL-CM01 binds to residues in the catalytic domain of 
PRMT5. We show that in addition to a few commonly shared binding sites with 
EPZ015666, PR5-LL-CM01 largely exhibits its quite unique binding sites to 
PRMT5 (Figure 35B), possibly contributing to the different efficacies we observed 
in the previous figures. Overall, the structural analysis gives us a valuable insight 
into various binding interactions that could be occurring between PR5-LL-CM01 
and PRMT5 and present a plethora of opportunities for further studies to verify 
these predicted interactions.  
 
4.2.11 Attempts to Determine Direct Binding Between PR5-LL-CM01 and PRMT5 
4.2.11A Using Sepharose Bead-based Conjugation Method to Study Binding 
Interaction of PR5-LL-CM01 with PRMT5 
In order to provide evidence of a direct binding interaction between PR5-
LL-CM01 and PRMT5, we decided to use CNBr-activated Sepharose beads to 
conjugate with the inhibitor and then incubated with cell lysate that contains the 
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target, PRMT5 to allow for the binding between the two. The beads were then 
pulled down, unconjugated from the inhibitor and its potential target PRMT5 that 
binds to the inhibitor could be detected using Western blotting with PRMT5-
specific primary antibody.  
 
We tried combinations of different tube sizes and milk concentrations for 
blocking the beads in order to reduce background due to non-specific binding to 
the beads. The 10% milk/15ml Falcon tube worked best to reduce the non-
specific background binding of PRTM5, in the absence of inhibitor conjugated to 
the beads (Figure 36A). When we used this condition for the experiment with 
PR5-LL-CM01, we did not observe any bands in the test sample (Figure 36B). 
One possibility for this result could be that the compounds did not bind to the  
beads well. One caveat to the usage of these specific beads is that they bind to 
compounds that contain primary amines in the structure, as per the 
manufacturer’s recommendations. However, PR5-LL-CM01 does not have 
primary amines, only a secondary amine in its structure. These beads have been 
shown in the past to conjugate with compounds containing secondary amines 
(Zhang et al., 2016), hence we decided to attempt it with our compound as well 
but did not have success. Looking at the docked structure in Figure 34, the 
reason for non-conjugation could be due to the fact the imino group of PR5-LL-
CM01 is within its binding pocket with PRMT5 and thus could be shielded from 












Figure 35. Postulation of PRMT5 Residues Interacting with PR5-LL-CM01 
A. Ligand affinity map in the SAM-bound condition, depicting the PRMT5 
residues interacted with PR5-LL-CM01. Different bonds or charges are 
symbolized on the right side of the figure. Key site, E444, is circled in red 
dotted line. B. Binding residue distribution diagram, illustrating the PRMT5 
residues that potentially bind to PR5-LL-CM01 alone (red font), EPZ015666 




concentration of drug we used might be too low. We decided that since the beads 
were not manufactured to interact with secondary amines and could lead to 
extensive troubleshooting and low chance of success, it would be wiser to look at 
other means to achieve this goal.  
 
4.2.11B Using Isothermal Calorimetry (ITC) Method to Study Binding Interaction 
of PR5-LL-CM01 with PRMT5 
As an alternative to the Sepharose beads approach, we decided to use 
the ITC method to test the binding interaction of PR5-LL-CM01 with PRMT5. ITC 
measures the heat change that occurs when molecules interact in solution 
(Holdgate 2001). A major advantage of this assay over the Sepharose beads 
approach was the lack of labelling/conjugation that was required to conduct the 
study. However, as we began designing experiments for optimizing the assay for 
our purpose, we quickly realized a major disadvantage of this assay was the 
large quantities of enzyme needed for each troubleshooting and/or optimization 
step. Every time, 1-1.2mg of Flag-tagged PRMT5 was purified from mammalian 
cell lines, which made the method extremely labor intensive, time-consuming and 
expensive. A representative ITC curve is depicted in Figure 37, when PR5-LL-
CM01 was added stepwise to the purified PRMT5 enzyme solution in the ITC 
instrument. This curve suggested that there could be slight turnover of the 
compound by the enzyme, as observed by the step-wise decrease in the curve. 
This trend could be because PR5-LL-CM01 bound to PRMT5 in the SAM binding 
site in the absence of SAM in this reaction, as predicted in Figure 34. However, 




Figure 36. Sepharose Bead-based Conjugation Method to Study Binding 
Interaction of PR5-LL-CM01 with PRMT5  
A. Western blot with conditions to optimize blocking (Eppendorf tube and 15ml 
Falcon tube; 5% and 10% milk) for reducing background caused due to non-
specific binding of components in the cell lysate to the Sepharose beads. In 
this experiment, the beads are not conjugated to the inhibitor, so one would 
expect no PRMT5 binding to the beads. 10% milk/15ml Falcon tube worked 
best in reducing the non-specific PRMT5 background band the most, upon 
probing for PRMT5 expression. B. Conjugation of beads with PR5-LL-CM01, 
followed by incubation with cell lysate and pulldown to detect PRMT5 did not 
show much success as no bands were observed when probed for PRMT5 
expression. Cycloheximide (CHX) was used as a non-specific protein that does 
not bind to the Sepharose beads 
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result due to heat changes that occur on account of buffer mismatch. Since 
massive troubleshooting was anticipated to verify these results and the 
purification of enzyme was not proving to be feasible, we decided to think about 
alternative approaches to this method as described in Chapter 6. 
 
4.2.11C Using Cellular Thermal Shift Assay (CETSA) Method to Study Binding 
Interaction of PR5-LL-CM01 with PRMT5 
In order to test the binding interaction of PR5-LL-CM01 with PRMT5 in 
PANC1 and HT29 cells, we used the CETSA approach. Unlike Sepharose beads 
and ITC, CETSA allows for assessment of the drug-target engagement in cells 
(Almqvist et al., 2016). The basic principle of this study involves thermal shifts 
that occur on account of compound binding to the target in cell lysates (Martinez-
Molina et al., 2013). Binding quantification was done using Western blotting with 
a specific antibody that can identify the target. We used the highly specific anti- 
PRMT5 antibody described in the Methods section for our purpose. Upon 
treatment with PR5-LL-CM01 for both PANC1 and HT29 cells, we observed an 
apparent shift in the melting curve of PRMT5 between the treated vs. untreated 
condition in both PANC1 and HT29 cells (Figure 38). However, variability 
between the two groups was high and therefore no statistically significant 






Figure 37. Isothermal Calorimetry (ITC) Approach to Assess Binding 
Interaction of PR5-LL-CM01 with PRMT5  
ITC curve showing the heat changes in solution in µJ/sec, when PR5-LL-CM01 
was mixed with PRMT5 over time. The step-wise decrease in the curve 
suggests that there could be slight turnover of the compound by PRMT5, if 
PR5-LL-CM01 could be binding to PRMT5 in the SAM binding site in the 
absence of SAM, as predicted in Figure 34. 
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Moving forward, I have proposed specific experiments in Chapter 6 that 
will help in better understanding of possible direct interactions between PR5-LL-
CM01 and PRTM5 in vitro. 
 
4.2.12 Dose Finding/Chronic Toxicity Study of PR5-LL-CM01 in NSG mice 
An important aspect of PR5-LL-CM01 efficacy that was untested so far 
was its potential in in vivo cancer models. Xenograft models of cancer have been 
well established as a means for early phase drug development to test efficacy in 
higher model organisms beyond mammalian cell lines cultured in a petri dish 
(Jung 2014). Hence, the next logical step was to test PR5-LL-CM01 in the in vivo 
models of PDAC and CRC. However, since this compound has never been 
injected in animal models before, it was imperative to do a preliminary study to 
determine dosages that would be appropriate for testing without being toxic to 
the animal. We decided to use mice originally developed at The Jackson 
Laboratory and bred in-house at the IVT for our purpose. NSG mice strain is 
extremely immunodeficient strain and they lack mature T cells, B cells, and 
natural killer (NK) cells (Ishikawa et al., 2005; Shultz et al., 2005). These 
immunodeficiencies allow engraftment of a wide range of human cells and 
enable sophisticated modeling of diverse areas of human biology and disease. 
This experiment was conducted in collaboration with the IVT core. Two dosages 
of PR5-LL-CM01, 20mg/kg and 50mg/kg, were injected 3X/week in the first week 
and single injection daily (SID) for the second week. Toxicity in terms of changes 





Figure 38. Cellular Thermal Shift Assay to Assess Binding Interaction of 
PR5-LL-CM01 with PRMT5  
Western blot to test the shift in melting curve for PRMT5, in the presence and 
absence of PR5-LL-CM01 treatment for A. PANC1 and B. HT29 cells 
respectively. A slight shift was observed for both cell lines upon compound 













Figure 39. Toxicity Study of PR5-LL-CM01 in NSG mice 
No changes in (Left panel) body weight and (Right panel) gait and posture 
were observed upon treatment of Vehicle Control, 20mg/kg and 50mg/kg over 




over the course of compound injection and no changes were observed in any of 
these parameters (Figure 39), thus informing that these dosages were not toxic 
to the mouse and this range could be used in further studies. However, it is 
important to consider that these mice do not mimic the human situation, which 
has a normal immune function and these toxicity studies will be replicated in 
normal mice in the future. 
 
4.2.13 Pharmacokinetic Study of PR5-LL-CM01 
In order to determine drug concentrations of PR5-LL-CM01 in 
pharmacological models, we first needed to characterize the pharmacokinetic 
(PK) properties of the compounds in mice. PK parameters allow us to get an idea 
of the absorption, distribution, metabolism and excretion properties of a 
compound in a chosen model system. In this case, we used NSG mice as our in 
vivo mouse model. Before conducting the in vivo study, we collaborated with Dr. 
David Jones at IU CPAC to develop a method for detection of PR5-LL-CM01 
using LC-MS. The details of method development shared by Dr. Jones are listed 
in Appendix C. Next, PK parameters of PR5-LL-CM01 were determined in NSG 
mice following a single I.P. dose administration of 20mg/kg followed by blood 
collection using facial saphenous vein at 1, 2, 4, 8, and 24 h. The plasma 
samples were then sent to the CPAC for detection of the PR5-LL-CM01 using the 
method developed previously. As observed in Figure 40, we observed a time-
dependent decrease in the plasma concentrations of PR5-LL-CM01, with an 
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almost entire elimination at 24 h post injection. The PK parameters are shown in 
Table 3. The half-life of the drug was calculated to be ~3.3 h.   
 
Furthermore, we collected tissue samples at 4 h and 24 h time points for 
pancreas and colon (sites for PDAC and CRC, respectively), to determine the 
amount of drug delivered to the target tissues. Interestingly, we could detect the 
presence of significant quantities of PR5-LL-CM01 at 4 h post injection in the 
pancreas and colon respectively, indicating that PR5-LL-CM01 was successfully 
delivered to the target tissues. Our data also suggested a complete clearance at 
24 h post injection (Figure 41). Further studies are needed with more time points 
to get a more elaborate idea of the tissue PK dynamics. Some potential 
experiments have been addressed in Chapter 6.  
 
4.2.14 Tumor Growth Pilot for PANC1 and HT29 using Subcutaneous Injection 
Before beginning tumor efficacy studies, it was important to determine the 
proper implant conditions for PDAC and CRC cells to be used for the same. In 
order to achieve this goal, we injected three different cell numbers of PANC1 
cells s.c. in NSG mice: 5X106, 8X106 and 10X106 cells per mouse. We then 
checked for growth kinetics over a period of time by measuring tumor volume at 
regular intervals (Figure 42A). 2000mm3 is the cutoff for tumor size for sacrifice 
as per the ethical regulations under the approved protocol. As shown in Figure 
42A here, 10X106 cells managed to reach the peak tumor volume of 2000mm3 at 




Figure 40. Plasma Pharmacokinetic Graph for PR5-LL-CM01 
Graph showing the presence of PR5-LL-CM01 in plasma in a time course of 
1,2,4,8,24h. With peak concentration at 1 h after 20mg/kg PR5-LL-
CM01injection, it is almost completely cleared out after 24 h. The half-life was 
calculated to be ~3.3 h. 
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Table 4. PK parameters of PR5-LL-CM01 
Dosage 20mg/kg 
Route of Administration i.p. 
Cmax 489ng/ml (1.2µM)  




Vdss/F 1.11 L 
Abbreviations:   
Cmax:  maximum concentration 
tmax:  time of maximum concentration 
AUC0-∞:  area under the plasma concentration-time curve from 0-infinity 
t1/2:  half-life 
Cl/F:  clearance/availability 
Vdss/F:  apparent volume of distribution 
Comments:   
Model: NCA-xls, non-compartmental using PK add ins 
All PK parameters were derived from average data.   
Assumed mouse weight was 25g.   






Figure 41. Tissue Pharmacokinetic Graph for PR5-LL-CM01 
Graph showing the presence of PR5-LL-CM01 in pancreas and colon tissue in 
a time course of 0, 4, and 24h. We observe PR5-LL-CM01 in both the 
pancreas and colon of the mice, and it is completely cleared at 24h. This 
indicates that PR5-LL-CM01 does reach the sites of where PDAC and CRC 





























Figure 42. Tumor Growth Pilot Study for PANC1 and HT29 Using 
Subcutaneous Injection 
Graph depicting tumor growth over time for A. PANC1 and B. HT29 cells when 
they were subcutaneously implanted respectively in NSG mice.  
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PANC1 cells per mouse for tumor implant. A similar tumor kinetic study was done 
for HT29 cells in NSG mice by injecting 1X106, 2X106 and 3X106 cells s.c., in 
collaboration with IVT. As observed in Figure 42B, 3X106 cells reached the 
2000mm3 mark at the earliest i.e. ~2 weeks and was the number we finalized for 
future implants using HT29 cells. 
 
4.2.15 Anti-tumor Efficacy Study for PR-LL-CM01 in a Subcutaneous Xenograft 
Model of PDAC and CRC 
Once we optimized the dosage and implant conditions, the next logical 
step was to conduct a tumor efficacy study in vivo. Either PANC1 or HT29 cells 
were subcutaneously xenografted into NSG mice and then treated with PR5-LL-
CM01 three times per week at 20mg/kg till the day the mice were sacrificed. 
Both body weight and tumor size were monitored during this process. As shown 
in Figure 43A, injection of PR5-LL-CM01 did not visibly affect the mice body 
weight. However, it led to significant tumor inhibition in both PANC1 and HT29 
(Figure 43B) xenografted mice, demonstrating the strong anti-tumor efficacy of 
PR5-LL-CM01 in both PDAC and CRC. 
 
4.2.16 Anti-tumor Efficacy Study for PR-LL-CM01 in an Orthotopic Xenograft 
Model of PDAC and CRC  
Orthotopic xenograft models involve introducing tumors directly into the 
organ of origin for the respective cancers. A main advantage of this model over 
s.c. type is the ability to have similar tumor microenvironments as the original   
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Figure 43. PR5-LL-CM01 displayed significant anti-tumor effect in vivo. 
A. No significant changes in body weight were observed over the course of 
treatment in either PANC1 or HT29 model after treatment with 20mg/kg of 
PR5-LL-CM01. (*P < 0.05, n = 4). B. Tumor efficacy study for PANC1 or HT29 
cells which were subcutaneously implanted in NSG mice. Inhibition of tumor 
growth was observed upon treatment with 20mg/kg of PR5-LL-CM01 
intraperitoneally for 3X/week, as compared to the vehicle control. (*P < 0.05, n 
= 4). 
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tumor and thus are considered to more closely resemble the human condition. 
Moreover, orthotopic mouse models develop metastasis which is rarely seen in 
the s.c. model (Qiu and Su, 2012). To this end, we collaborated with IVT to do 
orthotopic implants in NSG mice with PANC1 cells that contain a fusion protein 
with cDNA for the luciferase gene (Shannon et al., 2015). After the tumors were 
allowed to grow for 10 days, SID treatment with 20mg/kg PR5-LL-CM01 was 
initiated in these mice. Tumor sizes were measured using BLI imaging upon 
injection of a luciferase substrate as described in the Methods section. We 
observed a significant decrease in tumor size as per the emission measurements 
(Figure 44), with treatment with PR5-LL-CM01, as compared to the Vehicle 
control. These results are quite promising as they emphasize the tumor efficacy 
of PR5-LL-CM01 in a more advanced model system beyond the heterotopic s.c. 
model. Further studies with an orthotopic model for CRC will be conducted to 
understand the efficacy of PR5-LL-CM01 in this cancer. 
 
4.2.17 Generation of PR5-LL-CM01 Derivatives 
In our studies so far, PR5-LL-CM01 has displayed remarkable efficacy in 
inhibiting cancer progression. However, as we continue to do more in-depth 
studies, there are possibilities that we might run into efficacy issues. 
Alternatively, it would be prudent to develop a series of derivatives with 
comparable or ideally even higher efficacy than the parental control. In this 
regard, we collaborated with Dr. Lan Chen and Dr. Lifan Zeng from the IU 
Chemical Genomics Core, an expert chemist who used structure activity  
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Figure 44. PR5-LL-CM01 Displayed Significant Anti-Tumor Effect In An 
Orthotopic Model of PDAC  
A. Tumor efficacy study in an orthotopically implanted model of PANC1 cells 
demonstrated that tumor growth was inhibited upon intraperitoneal treatment 
daily with 20mg/kg of PR5-LL-CM01, as compared to the Vehicle control. 
Tumor load was measured using bioluminescent imaging and is represented 
as Total Flux. (*P<0.05, n=3-4) B. Representative BLI images showing the 
relative signal intensities for orthotopic implants in both groups. 
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relationship (SAR) analysis to synthesize several derivatives of PR5-LL-CM01. 
This involved maintaining the core structure from Figure 21, while making slight 
alterations to the surrounding chemical groups. In this way, Dr. Zeng designed 
and synthesized 20 derivatives of PR5-LL-CM01. Experimental procedures for 
derivative synthesis are expounded upon in Appendix B. Using MTT assays 
described previously, we tested the efficacy of these derivatives as compared to 
the parental compound in both PANC1 and HT29 cell lines. The IC50 values for 
this set of derivatives are summarized in Table 5. Only one derivative, PPA-1 
showed promise with comparable IC50 values in PANC1 and about ~5-fold lower 
IC50 value in HT29 cells. We decided to test this compound further in parallel with 
PR5-LL-CM01 in an in vivo model of PDAC and CRC as described in Section 
4.2.18.  
 
Furthermore, in collaboration with Dr. Olaf Wiest at University of Notre 
Dame, we used computer docking analysis to screen ChemDiv libraries with 
same core group as PR5-LL-CM01. 41 SAM-binding and 40 substrate binding 
pocket compounds were predicted from these libraries, out of which majority 
were screened out as they were already part of the ChemDiv library used for the 
first AlphaLISA HTS described earlier. We further focused on 16 unique 
compounds that were identified. Similar to the chemically synthesized 
derivatives, we used MTT assays to compare the efficacies of these structurally 
analogous compound as compared to Control. As described in Table 6, none of 





Table 5. MTT IC50 values for chemically synthesized PR5-LL-CM01 
derivatives by IU Chemical Genomics Core 
 
Name IC50 (μM) PANC1 IC50 (μM) HT29 
PR5-LL-CM01 (PARENT) 5 10 
1 STL 35 76 
2 PM-1-2 100 Did not reach 
3 PPA-1 4 2 
4 PTF-1 46 46 
5 PAM-1 38 27.5 
6 BBL 42 did not reach 
7 BAM-1 22 34 
8 BPM-1 16 8 
9 BTF-1 12 10 
10 BAP-1 15 69 
11 Pamhp-2-5 did not reach did not reach 
12 Pamhp-1 100 40 
13 Pamhp-6pm 79 40 
14 Pamhp-8tf 51 37 
15 Pamhp-3 did not reach 62 
16 Pamhp-5-5 did not reach 94 
17 Pamhp-9 13 41 
18 Pamhp-4-3 did not reach did not reach 
19 Pamhp-7 13 50 
20 Pamhp-10 5 4 
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Table 6. MTT IC50 values for compounds from ChemDiv libraries with 
similar core structure as PR5-LL-CM01 
 
 Name 
PANC1 (μM) HT-29 (μM) 









2 G932-0009 18 78 
3 G932-0014 6 >100 
4 G932-0018 30 >100 
5 G932-0173 15 >100 
SET 
2 




7 G932-0323 35 >100 
8 G932-0810 3 18 
9 K402-0890 12 
*see 
graph 
10 K405-2810 34 42 
SET 
3 




12 K402-0886 8 35 
13 K405-2750 3 25 
14 K402-2754 20 31 
15 G932-3035 12 15.5 
16 K402-1019 >100 6 >100 10 
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or the promising derivative PPA-1 collectively for PDAC and CRC cell lines. 
Finally, moving forward, we would focus on PPA-1, while also continue the SAR 
analysis to better understand the active parts of the compound structure and 
check if manipulations in these can significantly improve the efficacy of the 
parental compound. 
 
4.2.18 Anti-tumor Efficacy Study for PR5-LL-CM01 Derivative PPA-1 in a 
Subcutaneous Xenograft Model of PDAC and CRC 
Next, we wanted to test the in vivo tumor efficacy of our most promising 
inhibitor from our in vitro studies, PPA-1 in comparison to PR5-LL-CM01 in vivo. 
What we observed was that the activity of PPA-1 was comparable to PR5-LL-
CM01 in decreasing tumor size in NSG mice for both PDAC and CRC cells 
(Figure 45A and B; upper panels). Additionally, there was no visible effect on 
the mice body weight between the compound or Vehicle-treated groups (Figure 
45A and B; lower panels). Based on these observations, PPA-1 seemed to be 
much more effective in vitro and comparable to the parental compound in vivo. We 
will continue to further look for even more derivatives which shows several folds 
difference in efficacy as compared to the parental compound in vitro and vivo. 
 
4.3 Concluding Remarks 
Collectively, the above experiments demonstrated that we have 
successfully developed a PRMT5-specific AlphaLISA HTS technique by which 
we discovered a novel PRMT5 inhibitor, PR5-LL-CM01. Furthermore, we  
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Figure 45. PPA-1 Displayed Significant Anti-Tumor Effect In Vivo 
Tumor efficacy study for A. PANC1 and B.  HT29 cells which were 
subcutaneously implanted in NSG mice. Inhibition of tumor growth was 
observed upon intraperitoneal treatment for 3X/week with 20mg/kg of PR5-LL-
CM01 as well as its derivative PPA-1 respectively, as compared to the Vehicle 
control (Upper panels). No significant changes in body weight were observed 
over the course of treatment in either PANC1 or HT29 model after treatment 
with 20mg/kg of PPA-1 or PR5-LL-CM01 (Lower panels). (*P<0.05, n=4). 
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showed that PR5-LL-CM01 and its promising derivative PPA-1 were able to 
reduce tumor formation in both in vitro and in vivo models of PDAC and CRC. 
Additionally, we also presented evidence for specificity of PR5-LL-CM01 for its 
target, PRMT5 and the subsequent effect of PRMT5 inhibition on our substrate of 
interest, NF-kB. Our studies highlight the significant therapeutic potential of 
PRMT5 in PDAC and CRC. These findings lay a solid foundation for further 
studies with PR5-LL-CM01 and its derivatives. These efforts may eventually lead 
to clinical trials in the near future.  In the next chapter, we elaborate on efforts to 
explore even more inhibitors of PRMT5 by running a second round of HTS using 
compound libraries containing natural compounds and bioactives, distinct from 
the first round described here containing small molecule compounds. 
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CHAPTER 5. ADDITIONAL INHIBITORS OF PRMT5 FROM HIGH 
THROUGHPUT SCREEN #2 
5.1 Background and Rationale 
In order to take a drug candidate from bench to clinic, there are several 
early phase efficacy studies in the lab that need to be performed using in vitro and 
in vivo models (similar to the ones detailed in Chapter 4). This is followed by a 
lengthy and arduous process of testing the safety, toxicity and efficacy in human 
patients before the drug can make it to the clinic, besides the time and financial 
resources involved. Also, the chances of failure remain high, with 1 in 10,000 
compounds making it from the bench to bedside. 
  
In the previous chapter, we discovered a novel inhibitor of PRMT5, namely 
PR5-LL-CM01 that was effective in in vitro and in vivo models. PR5-LL-CM01 was 
identified using an HTS screen on chemically synthesized compound libraries. The 
current chapter details the attempt of a second HTS with a separate set of libraries 
that contained natural, semi-natural products and known bioactives. The goal was 
to check if we find even more promising inhibitors of PRMT5 with better efficacy, 
specificity or both, as compared to the currently available options. This also 
demonstrates the power of our optimized AlphaLISA protocol to identify 
compounds that can inhibit the activity of the target of interest, in this case PRMT5. 
We identified two top hits in the second screen, P1608K04 and P1618J22 which 
showed efficacy and specificity in PDAC and CRC cells. However, they were not 
as efficacious as PR5-LL-CM01 in inhibiting PRMT5 and the subsequent NF-kB 
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activation, as higher concentrations of these compounds were needed with respect 
to PR5-LL-CM01 to observe similar effects. However, these compounds could 
prove to be useful for future in other cancers in which PRMT5 is overexpressed, 
depending if their efficacy is affected by other factors that are unique to the 
respective tumor microenvironment. However, detailed studies would need to be 
done to test this possibility. Furthermore, derivatives with better activity than 
parental compounds and PR5-LL-CM01 could be generated. Overall, the 
AlphaLISA method is an effective methodology to identify promising drug 
candidates for specific targets in early phase drug discovery. 
 
5.2 Results 
5.2.1 High Throughput Screen Design: Z’ Experiment and Quenching 
The second round of HTS was designed using the same exact protocol as 
illustrated in Table 1 and described in detail in Chapter 4. However, there was 
an extra step we added in order to eliminate any “false hits” which is discussed 
here. However, as a first step right before running an HTS, it is always advisable 
to run a Z’ experiment to make sure the assay is robust enough to be used for 
large-scale screening on a repeated basis. We had run a Z’ test before our first 
HTS as described in Chapter 4.2.2. Prior to running the second HTS here, we 
reran the Z’ experiment mainly because we prepared a different batch of enzyme 
prep and used a different batch of beads. The Z’ factor was calculated to be 0.7 
(Figure 46). A Z’ factor >0.5 is considered to be robust enough to be used for 








Figure 46. Determination of Z’ Factor for PRMT5-specific AlphaLISA 
Assay 
Scatter plot, representing the data points for the 384-well plate, with the red 
points indicating the ‘‘maximum signal’’ wells and the purple points 
representing the ‘‘background’’ wells. The solid lines at the center represent the 
average values and the dotted lines at the top and bottom represent +/- 3 C SD 
(standard deviation) values for the respective groups. The S/B (signal vs. 
background) ratio was calculated to be 8.3 and the Z’ factor was determined to 
be 0.7. 
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324 compounds displayed apparent capacity to inhibit PRMT5 
methyltransferase activity. These hits were ranked based on their percent 
inhibition values.  However, unlike the library used in the first screen, several of 
the compounds used in the second screen were colored in nature and thus could 
autoluminesce. This could lead to the false hits due to interference with the 
AlphaLISA assay itself rather than inhibiting the enzymatic reaction, resulting in 
quenching of the Alpha signal. Thus, in order to obtain a more accurate list of 
positive hits, it was imperative to rule out these “Alpha signal quenchers”. One 
way to eliminate them was to screen those compounds in a control assay, in 
which only histone H4 pre-methylated at arginine 3 (Biotin-H4R3me2) was used 
without adding the PRMT5 enzyme. Under this experimental condition, the 
Biotin-H4R3me2 peptide will bring the Donor beads and Acceptor beads in close 
proximity to produce the Alpha signal. In this case, if any compound reduced the 
Alpha signal, it would be a quencher instead of a real inhibitor. This is because 
this reduction in signal is unrelated to PRMT5 activity which itself is absent from 
this reaction.  
 
Figure 47 illustrates the experimental design and plate layout for this 
filtering experiment among 320 top hits from the HTS screening to eliminate any 
Alpha signal quenchers. The first and last two columns did not contain 
compounds, but the first two columns had the pre-methylated peptide substrate 
which resulted in a high signal; the last two columns did not have me-H4R3 
substrate and provided the readings for the background signal. Every well of the 
133 
   
 
Figure 47. Plate Design for Quenching Experiment to Identify False 
Positive Hits from AlphaLISA screen 
The first two columns (white dots; grey background) do not contain any 
compound and act as positive controls, signifying ‘‘maximum signal’’. Columns 
1-22 had a Biotin-H4R3me2 substrate (dimethylated Biotin-H4R3) added at a 
final concentration of 15 nM in each well. The last two columns do not have the 
Biotin-H4R3me2, and act as the ‘‘negative control’’. Acceptor and donor beads 
were added to each well. No PRMT5 enzyme was included in this experiment. 
Compounds that exhibited quenching of the Alpha signal were ‘‘false hits’’ and 
not true PRMT5 inhibitors, and thus were removed from further testing. 
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plate had both the Acceptor and Donor beads. We identified 64 potential hits that 
were not false positives and repeated the AlphaLISA to reconfirm their inhibition 
activity. Several top hits were identified after this rigorous screening process with 
a cut-off value of over 60% inhibition and were further tested using AlphaLISA 
assays. The two most promising hits, P1608K04 and P1618J22 were identified 
as described in the next section. To summarize, we used a systematic screening 
approach to identify two top hits from a large pool of candidates, as illustrated in 
Figure 48A. 
 
5.2.2 Identification of Top Hits P1608K04 and P1618J22 
We conducted preliminary testing on the initial hits using the AlphaLISA 
assay to check for corresponding effect on PRMT5 methyltransferase activity. 
Through this testing, P1608K04 and P1618J22 (Figure 48B) showed the most 
promise. In a confirmation experiment, we observed that increased 
concentrations of both P1608K04 and P1618J22 led to a concurrent decrease in 
AlphaLISA signal with low IC50 values of ~1.5μM and 16.5μM, respectively 
(Figure 49A and B). Thus, we employed a stepwise protocol for screening 
~10,000 compounds using an AlphaLISA-based approach and identified two 





Figure 48. Identification of Top Hits P1608K04 and P1618J22  
A. Workflow for the stepwise procedure that eventually led to the shortlisting of 
two top PRMT5 inhibitors, P1608K04 and P1618J22, among ~10,000 
compounds from small compound libraries. Each step represents the 
experimental approach and the number of compounds to start with.  






Figure 49. Determination of IC50 using the AlphaLISA Assay 
A. Calculation of the IC50 of P1608K04 using AlphaLISA, showing a 
concentration-dependent decrease in the Alpha signal. The IC50 was ~1.5μM. 
B. The IC50 of P1618J22 was calculated to be 16.5μM, using the same 





5.2.3 P1608K04 and P1618J22 are Potent PRMT5 Inhibitors In Vitro 
In order to test the effectiveness of these promising PRMT5 inhibitors in 
the context of PDAC and CRC, we used the MTT assay with increasing 
concentrations of P1608K04 and P1618J22 in PDAC and CRC cell lines. Both 
P1608K04 (Figures 50A and C) and P1618J22 (Figures 50B and C) showed 
great efficacy in decreasing the cell viability in PDAC (PANC1, MiaPaCa2, and 
AsPC1) and CRC cells (HT29, HCT116, and DLD1).  Importantly, both 
compounds were much more potent (have lower IC50) than the commercial 
PRMT5 inhibitor EPZ015666 in PDAC and CRC cells (Figure 24). Therefore, our 
data suggested that P1608K04 and P1618J22 are powerful PRMT5 inhibitors in 
PDAC and CRC cells. Furthermore, the inhibitors identified using our PRMT5-
specific AlphaLISA assay could be used as tools to further study PRMT5-driven 
mechanisms in these cancers. 
 
5.2.4 P1608K04 and P1618J22 Inhibited PRMT5-mediated NF-kB Methylation 
and Downstream Activation  
To test the specificity of PRMT5 inhibitors, we examined their effect on 
p65 methylation and subsequent activation in both PANC1 and HT29 cells. The 
first thing we tested was the effect of compound treatment directly on the 
methylation of p65. In order to detect methylation specifically at the R30 site by 
PRMT5, we generated a site-specific antibody in collaboration with Genscript Inc. 
Western analysis with this site-specific antibody against dimethylated R30 
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Figure 50. P1608K04 and P1618J22 are Potent Inhibitors for Viability in 
PDAC and CRC Cells 
A. MTT assay with the treatment of P1608K04 in both PDAC (PANC1, 
MiaPaCa2, and AsPC1) and CRC cells (HT29, HCT116, and DLD1), showing 
that cell viability dramatically decreased in the presence of increasing 
concentrations of P1608K04. B. MTT assay with the treatment of P1618J22 in 
both PDAC and CRC. The data represent the means + SD for three independent 
experiments. C. Table summarizing the IC50 values for P1608K04 and P1618J22 
in PDAC and CRC cells, respectively. 
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residue of p65 showed decreased R30 methylation on p65 after the treatment of 
P1608K04 or P1618J22 (Figures 51A and B), confirming that these inhibitors 
specifically attenuated PRMT5-mediated NF-kB methylation in these cells. 
 
We had shown earlier that increased methylation resulted in increased 
NF-kB activation (Wei et al., 2013). In this regard, we used the NF-kB luciferase 
assay to determine the effect of compound treatment on PRMT5-mediated NF-
kB activation in PDAC and CRC cells. We confirmed that treatment of P1608K04 
and P1618J22 for 48 h at the indicated concentrations significantly decreased 
NF-kB activity in both PANC1 (Figure 52A) and HT29 (Figure 52B), 
respectively. It is important to note that it requires a much higher concentration of 
the commercial PRMT5 inhibitor EPZ015666 (~50-95μM in PANC1 and 190μM in 
HT29 cells) to observe a similar effect, demonstrating that both P1608K04 and 
P1618J22 are more effective than EPZ015666 in decreasing PRMT5-mediated 
NF-kB activation in PDAC and CRC cells (Figure 28). 
 
Since NF-kB R30 methylation leads to its activation, we wondered 
whether P1608K04 and P1618J22 may inhibit NF-kB activation and its target 
gene expression.  In addition to the above evidence, since PRMT5-mediated NF-
kB activation leads to the induction of well-known cancer-promoting NF-kB target 
genes, such as interleukin 8 (IL8) and tumor necrosis α (TNFα) in PDAC and 
CRC cells, we conducted qPCR to determine the effect of P1608K04 and 




Figure 51. P1608K04 and P1618J22 Decreased Methylation at R30 on the 
p65 Subunit of NF-kB 
Western blot analysis showing A. PANC1 and B. HT29 cells were treated with 
P1608K04 (left panels) or P1618J22 (right panels) at their IC50 values, 
respectively. Samples were probed with specific anti-p65-R30me2 antibody. 
Decreased p65-R30me2 levels were observed in the compound treated groups 
as compared with the control (Ctrl) groups that are without compound 





Figure 52. P1608K04 and P1618J22 Inhibited NF-kB Activation and its 
Target Gene Expression in PDAC and CRC Cells 
NF-kB luciferase assay in A. PANC1 and B. HT29 cells, indicating that 
treatment with increasing concentrations of P1608K04 or P1618J22 
respectively for 48h led to a corresponding decrease in NF-kB activation. The 
data represent the means + SD for three independent experiments. *P<0.05 vs. 








Figure 53. P1608K04 and P1618J22 Inhibited NF-kB Target Gene 
Expression in PDAC and CRC Cells 
qPCR analysis, showing that the expression of the typical NF-kB target genes, 
IL8 and TNFa, was decreased after the treatment with P1608K04 or P1618J22 
respectively in A. PANC1 and B. HT29 cells. The data represent the means + 
SD for three independent experiments. *P<0.05 vs. 0μM. 
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Figure 54. In Silico Prediction of P1608K04 and P1618J22 Binding to 
PRMT5 
A-D. Binding poses predicted for P1608K04 and P1618J22. (A and C), in the 
presence or B and D. in the absence of SAM, respectively. PRMT5 is shown in 
gray ribbons, while all ligands are shown in balls and sticks and colored with 
respect to atom type (O atoms in red, N atoms in blue, S atoms in yellow. C 
atoms are colored in purple, orange, and cyan in SAM, EPZ015666, and the 
P1608K04 or P1618J22, respectively.) In panels B and D, the position of SAM 
is depicted with a purple wireframe surface to indicate if the docked ligand 
overlaps. E. Docking scores for the docking poses depicted in A-D. 
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treatment of PANC1 (Figure 53A) or HT29 (Figure 53B) cells with these two 
compounds led to significantly decreased expression of both IL8 and TNFα. 
Collectively, the above evidence affirmed that P1608K04 and P1618J22 are 
PRMT5 specific inhibitors that function through inhibiting PRMT5-mediated NF-
kB methylation, activation, and its downstream target gene expression.  
 
5.2.5 Predicted Structural Binding of P1608K04 and P1618J22 to PRMT5 
To better understand the potential binding mechanism of P1608K04 and 
P1618J22 to PRMT5, we used a directed computer-based docking approach of 
these inhibitors to the PRMT5 crystal structure. This approach was similar to the 
one used to study PR5-LL-CM01 binding to PRMT5 and was conducted in 
collaboration with Dr. Ozlem Demir at the University of California, San Diego 
under the guidance of Dr. Rommie Amaro. Comparing the crystal structure of 
commercial PRMT5 inhibitor EPZ015666 with the predicted binding poses of the 
two inhibitors we identified, we explored how our inhibitors bound in conjunction. 
We also included EPZ015666 in the analysis to check if there is any overlap in 
residues that interact with our compounds vs. EPZ015666. As illustrated in 
Figures 54A and B, the most energetically favorable interaction for P1608K04  
has been depicted in the presence (SAM-bound PRMT5) and absence (Apo-
PRMT5) of the methyl donor SAM, respectively. As shown in Figures 54A, 
P1608K04 binds to a similar location to that of EPZ015666 in the presence of 
SAM. Interestingly, in the absence of SAM (Figure 54B), P1608K04 partially 
occupies the SAM binding site, thereby potentially blocks the SAM-PRMT5 
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interaction. Blocking SAM binding could be a potential avenue through which 
PRMT5 methyltransferase activity is affected. Based on the docking scores listed 
in Figure 54E, P1608K04 is more likely to bind in the absence of SAM. 
 
In the case of P1618J22, we observed a similar binding pose to that of 
EPZ015666 which barely overlaps with the SAM binding site in the presence of 
SAM. On the other hand, we observed a preferential binding to the SAM binding 
site in the absence of SAM (Figures 54C and D). However, for P1618J22, 
binding affinities are very close in the presence or absence of SAM, thus it is 
impossible to predict which pose the ligand would prefer solely based on 
structural docking studies.  
 
Next, we wanted to find residues on PRMT5 that closely interact with the 
respective compounds. The ligand affinity maps in Figure 55 illustrate the 
PRMT5 residues that can potentially interact with P1608K04 (Left panels) or 
P1618J22 (Right panels), in the presence (upper panels) or absence (lower 
panels) of SAM, respectively. Key residues unique to the PRMT5 protein are 
involved in these compound interactions as well. Notably these include the E444 
residue that is part of the catalytic cleft of PRMT5 and a F327 residue critical for 
PRMT5 product specificity. The interactions also differ from EPZ015666, possibly 
leading to the different efficacy between P1618J22 and P1608K04, with the latter 
showing slightly higher predicted binding affinity (Prabhu et al., 2017). In future, it  
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Figure 55. Ligand Affinity Maps for P1608K04 and P1618J22 Binding to 
PRMT5 
Ligand affinity maps depicting the residues of PRMT5 that interact with A. 




will be interesting to explore how important these residues (Figures 55A and B) 
are in the binding mechanism of these inhibitors to PRMT5.  
 
5.3 Concluding Remarks 
Collectively, our data support that inhibitors of PRMT5 such as P1608K04 
and P1618J22, like PR5-LL-CM01 inhibit PRMT5-mediated NF-kB activation and 
its downstream target gene expression in PDAC and CRC. As a whole, PR5-LL-
CM01 was the superior PRMT5 inhibitor in terms of efficacy and was the one we 
focused on for majority of the studies presented in this thesis and in the future. 
However, this study also emphasizes the power of AlphaLISA technique and the 
ability to harness it to identify novel inhibitors of a desired epigenetic target, in 
this case PRMT5. Going forward, AlphaLISA can be adapted for the target of 
choice to perform a successful HTS and identify robust inhibitors for the 
respective targets that could serve as tools in research and/or in the clinic. 
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CHAPTER 6: DISCUSSION 
6.1 Summary of Findings and Discussion 
As summarized in Figure 56, based on the data from Chapters 3-5, we 
hypothesize that PRMT5 is a tumor promoting factor in PDAC and CRC. Novel 
inhibitors of PRMT5, such as PR5-LL-CM01, P1608K04, and P1618J22, may 
inhibit the PRMT5-mediated NF-kB activity, therefore decrease its target gene 
expression, alleviate cancer related characteristics, and impede cancer 
progression. Detailed summaries and discussion will be elaborated below.  
 
6.1.1 Current Therapeutic Limitations and Challenges in PDAC and CRC 
Treatment 
PDAC and CRC are among the leading causes of cancer-related deaths in 
the United States. New PDAC and CRC cases were estimated to be 53,670 and 
135,430 and deaths in this year were estimated at 43,090 and 50,260 
respectively in men and women combined in the US for 2017 (Howlader et al., 
2017). This is equivalent to 15% of the total cancer-related deaths in the US and 
these numbers keep rising every year. Despite important advances in recent 
years, many patients continue to experience disease recurrence following 
primary therapy. Both these diseases primarily occur through somatic mutations 
that can accumulate over time and lead to cancer progression. Furthermore, 
these cancers are well-known to metastasize to other parts of the body, thereby 




Figure 56. Hypothetical Model 
The optimized AlphaLISA screen for PRMT5 inhibitors identified and confirmed 
the major inhibitor, PR5-LL-CM01 and two other inhibitors, P1608K04 and 
P1618J22. We demonstrated that this inhibitory effect could partly be via 
inhibiting PRMT5-mediated NF-kB methylation and subsequent activation, 
resulting in decreased cancer-associated target gene expression. This process 
would ultimately lead to the alleviation of cancer phenotype and overall 
highlights the significance of PRMT5 as a tumor promoter and its therapeutic 





“no cure” for a significant number of patients presenting with metastasis upon 
diagnosis. Finally, an estimated nearly $20 billion were spent on PDAC and CRC 
care in the United States in 2016, reflecting the urgent medical need for the 
discovery of newer PDAC and CRC treatment options. In this regard, The White 
House Cancer Moonshot was established in 2016 by then Vice-President Joe 
Biden, with the aim to double the rate of progress in cancer research and 
treatment over the next five years.  
 
The treatment for both these cancers is dominated by chemotherapeutic 
drugs that interfere with DNA synthesis that target rapidly dividing tumor cells. 
One chemotherapeutic drug may be prescribed on its own or more, depending 
on the cancer stage as well as inherent health of the patients. Besides not being 
specific, standard chemotherapy such as the combination of drugs termed as 
FOLFIRINOX for PDAC and FOLFOX for CRC described before (Chapter 1) can 
have cause a number of side effects. These include fatigue, hair loss, 
susceptibility to bruising and bleeding, anemia, nausea and vomiting amongst 
others that take a physical and emotional toll on the patients. Thus, there is a 
clear unmet need for more targeted therapeutics to treat these diseases.  
 
Specific cellular factors that are significantly upregulated more in cancer 
cells over normal cells can be indicative of a dependence on these oncogenic 
factors for sustaining the tumor. Modulation of such factors using targeted 
inhibitors can prove to be an effective therapeutic measure. A caveat to this 
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rationale is that some of these factors can be critical in normal cell function and 
complete inhibition can lead to undesired detrimental effects. Thus, identification 
of upstream or downstream regulators that can partly affect function of these 
factors is useful, as modulation of activity via these regulators rather than 
absolute direct inhibition could result in alleviation of the cancer phenotype while 
still having negligible effects on normal cells. Of course, these upstream or 
downstream regulators themselves might be critical in normal cells. In the case of 
PRMT5, it has been shown to be critical in immune function regulation, 
embryonic development and regulator of normal adult hematopoiesis (Zheng et 
al., 2017; Liu et al., 2015; Gkountela et al., 2014). However, PRMT5 is also a 
critical player in cancer and inhibition of PRMT5 can lead to a decrease in the 
cancer phenotype as described in this thesis and others, when we demonstrated 
PRMT5 as a critical activator of a major tumor promoting factor, NF-kB that is 
constitutively activated in PDAC and CRC. Furthermore, we identified a specific 
PRMT5 inhibitor, PR5-LL-CM01 with promising therapeutic implications in these 
deadly cancers. However, in order to prevent deleterious effects caused by non-
specific inhibition of PRMT5 in normal cell function, optimal dosing ranges and 
targeted delivery will need to be considered with future studies. 
 
6.1.2 PRMT5 Promotes PDAC and CRC Progression via NF-kB Activation 
PTMs regulate protein function in eukaryotes and have been shown to 
play important roles in a variety of cancers (Karve and Cheema 2011). 
Methylation of lysine and arginine is one of the most critical PTMs seen in nature 
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and are responsible for regulating a variety of signaling pathways in a cell. 
Changes in expression during disease states such as cancer can have critical 
implications directly or indirectly via downstream signaling pathways on disease 
progression. Indeed, in recent times, epigenetic enzymes have emerged as 
viable drug targets. An understanding of underlying signaling mechanisms 
implicated in cancer can help to design better drugs against these factors. Our 
lab recently discovered a novel PTM (arginine methylation) on a known tumor 
promoter, NF-kB, which in turn led to the activation of NF-kB (Wei et al., 2013). 
The epigenetic enzyme PRMT5 was identified for being responsible for this 
modification. Activation of NF-kB has been shown to aggressively promote 
PDAC and CRC phenotype as well as contribute to chemotherapeutic resistance 
in the past (Hai et al., 2016, Hassanzadeh 2011). Thus, identification of 
pathways/factors that can influence this activation could help limit it. Based on 
this exciting discovery, we hypothesized that PRMT5-mediated NF-kB activation 
could be important for promotion of PDAC and CRC phenotype, with the ultimate 
intent to develop PRMT5 as a therapeutic target for these deadly cancers by 
inhibiting its activity. 
 
In this study, we showed that PRMT5 expression was significantly 
upregulated in PDAC and CRC, as observed in cancer cell lines as well as tumor 
tissue from patients. Furthermore, increased expression of PRMT5 in cancer 
cells led to enhanced cancer-promoting characteristics, including cell 
proliferation, anchorage-independent growth and cell migration, clearly 
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highlighting the role of PRMT5 as a tumor promoting function in PDAC and CRC. 
Furthermore, to determine its effect on to NF-kB activity, we conducted luciferase 
assays with a consensus binding sequence for NF-kB located upstream of the 
luciferase reporter gene and showed that PRMT5 indeed promoted NF-kB 
activation in PDAC and CRC. Furthermore, NF-kB is a transcription factor and 
can translocate to the nucleus upon activation to promote expression of several 
genes that are critical for cancer phenotype. qPCR analysis showed that PRMT5-
mediated NF-kB activation promoted the expression of its well-known 
downstream target genes, indicative of the critical role of PRMT5 in NF-kB 
activation in PDAC and CRC. Overall, these studies emphasize the significance 
of PRMT5-mediated NF-kB activation for cancer promotion in PDAC and CRC. 
 
While its relationship to NF-kB is significant, it is necessary to consider 
that PRMT5-mediated signaling in a cell can be complicated. PRMT5 and NF-kB 
can both have different signaling mechanisms they could target besides each 
other. We acknowledge that the PRMT5-NF-kB axis studied here represents one 
aspect of the signaling spectrum that could be occurring in the tumor 
microenvironment. Recent studies have highlighted the dependence on PRMT5 
due to disruption of metabolic activities in cancers and inhibition of PRMT5 led to 
detrimental effects in the tumor cells (Mavrakis et al., 2016). PRMT5-mediated 
methylation of substrates beyond NF-kB, such as p53, EFGR, E2F-1 and 
histones have also been predicted to have an oncogenic role (Hsu et al., 2011, 
Yuan et al., 2012, Jansson et al., 2008). However, these studies have been done 
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in a variety of different cancers and the observed results can be very context-
dependent and specific to the cell or tissue type being studied. Understanding 
the signaling pathway that leads to the specific subtypes would allow to explore 
possible crosstalk between various PRMT5-driven signaling pathways that 
contribute to cancer promotion in these subtypes. It will also allow us to tease out 
any possible interactions between other signaling mechanisms and PRMT5-
driven axis that collectively contribute to NF-kB activation and opens up a 
gateway for exciting research in the future. 
 
Hence, even though many mechanisms underlying the role of PRMT5 in 
cancer are still unclear, the insights provided by this study are highly valuable in 
understanding the workings of PRMT5. They could perhaps also be applied to 
other cancers beyond PDAC and CRC. Both NF-kB and PRMT5 are upregulated 
in various types of cancers, including but not limited to pancreas, colon, breast, 
prostate, and lung cancers, as well as lymphoma and melanoma (Jiang and 
Newsham, 2006; Gu et al., 2012; Cho et al., 2012; Zhang et al., 2014; Wang et 
al., 2008). Due to the commonality of high levels of PRMT5, our current findings 
with regards to PDAC and CRC could have broader impacts on the 
understanding of cancer progression as a whole. 
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6.1.3 PR5-LL-CM01 is a Potent PRMT5 Inhibitor and Shows Anti-Tumor Efficacy 
in Disease Models of PDAC and CRC 
NF-kB is a critical transcription factor that is hyperactivated in various 
cancers (Wei et al., 2013). Since it also plays a crucial role in normal cellular 
functioning, direct targeting of NF-kB has not proven to be a successful 
therapeutic approach, as previous attempts for complete inhibition has resulted in 
severe cell death even in normal cells (Martin et al., 2016). These obstacles 
highlight the importance of identifying pathway-specific inhibition of NF-kB 
activity in cancer treatment. Thus, upstream modulators of NF-kB activity could 
be targeted, such as inhibitors directed towards the degradation machinery of 
inhibitor IkBα that sequesters NF-kB in the cytoplasm (Figure 3) or inhibitors of 
the mTOR pathway that can activate NF-kB through a series of downstream 
signaling events (Dan et al., 2008). All these different pathways could modulate 
different aspects of the disease etiology and a better understanding of the 
signaling mechanisms can help in determining the best multi-pathway therapeutic 
strategies. In this regard, the discovery of PRMT5-mediated activation of NF-kB 
and its targeted inhibition in PDAC and CRC is of great importance and 
significance. Furthermore, the successful development and application of the 
PRMT5-specific AlphaLISA HTS technique in this study constitutes another layer 
of unique contribution to the drug discovery field. Using this sensitive approach, 
we successfully identified PR5-LL-CM01 as our leading hit and confirmed that it 
is a highly potent and specific PRMT5 inhibitor (Figure 21). Using a closely 
related structural analog, PR5-LL-IEC01, we demonstrated the selectivity of the 
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effect shown by PR5-LL-CM01 (Figures 30, 32-33). When we first began 
developing the assay to screen for PRMT5 inhibitors, there were no known 
PRMT5 inhibitors in existence. Since then, Epizyme Inc. developed EPZ015666 
as the first-ever selective PRMT5 inhibitor that is commercially available (Chan-
Penebre et al., 2016). They reported that EPZ015666 was very effective in 
inhibiting mantle cell lymphoma. Since we were curious how EPZ015666 would 
work in a direct comparison to PR5-LL-CM01, we decided to test its efficacy in 
our PDAC and CRC models. We showed that PR5-LL-CM01 was ~10-15 fold 
more effective than EPZ015666 in PDAC and CRC models, making PR5-LL-
CM01 the first PRMT5 inhibitor to be highly effective in the treatment of solid 
tumors (Figures 23-24). We speculate that PR5-LL-CM01 could be more 
effective than EPZ015666 in the treatment of other solid cancers with hyper 
PRMT5 expression and would be exciting to test this possibility in the future.   
 
Additionally, using Western blotting we showed that there was a decrease 
in p65 methylation in vitro upon PR5-LL-CM01 treatment, demonstrating that the 
effect of this inhibitor observed in cells could be via decrease in PRMT5-
mediated NF-kB methylation and subsequent activation (Figure 27). We also 
conducted a screen to check for the specificity of inhibition of arginine 
methyltransferase family members activity via PR5-LL-CM01 and demonstrated 
that it was highly selective for PRMT5 over other PRMTs (Figure 31). More 
importantly, we also tested the toxicity and efficacy of PR5-LL-CM01 in animal 
models of PDAC and CRC. We observed no obvious toxicity up to 50mg/kg of 
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PR5-LL-CM01 in the mice (Figure 39). Treatment with 3X/week demonstrated a 
significant decrease in tumor size in both PDAC and CRC models, showing great 
promise to be tested further for clinical efficacy (Figure 43). In addition, we 
generated derivatives to check if we could increase the efficacy of the parental 
compound and found that PPA-1 was the most promising derivative so far (Table 
4, Figure 45). Further efforts to understand PPA-1’s efficacy and generate even 
more derivatives have been described in Section 6.3. 
 
Moreover, we used structural modeling experiments to understand the 
possible mechanisms through which that PR5-LL-CM01 could interact with 
PRMT5. We also looked into comparing these interactions with those of 
EPZ015666 and found that both these inhibitors interact with PRMT5 through 
quite different mechanisms (Figure 34). Particularly, PR5-LL-CM01 interacts with 
E444 on PRMT5, a critical residue for the catalytic activity of PRMT5 
(Antonysamy et al., 2012). F327 is another residue implicated in contributing to 
the specific symmetric dimethylation activity of PRMT5. Interestingly, we 
observed that all the residues participating in the binding interactions between 
PR5-LL-CM01 and PRMT5 span over the Rossman fold and β-barrel domains of 
PRMT5, which have been previously shown to comprise the catalytic 
methyltransferase domain of PRMT5 and the region where SAM and its 
substrates bind. On the other hand, EPZ015666 binds to PRMT5 independent 
from SAM binding sites (Figure 35). These quite different PRMT5 binding 
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mechanisms could shed light on why PR5-LL-CM01 is more selective than 
EPZ015666 in killing PDAC and CRC cells, but need to be further tested.  
  
All these studies have highlighted the potential of PRMT5 as viable target 
and PR5-LL-CM01. Further experiments to explore the efficacy and mechanism 
of action of PR5-LL-CM01 in PDAC and CRC are elaborated on in Section 6.3. 
  
6.1.4 Development of AlphaLISA as a Powerful Tool to Identify Potent Inhibitors  
Epigenetic modifications play an important role in normal cellular function 
and development in nearly every aspect of biology, making it one of the most 
important fields in scientific research. Dysregulation of epigenetic modifications 
leads to serious disruptions of regular functioning in humans and is the 
underlying cause of promoting a wide range of disorders including cancers. A 
plethora of studies have linked overexpression of epigenetic enzymes with 
promotion and metastasis of varied cancers. Thus, a great deal of interest has 
been generated in the field to exploit these epigenetic enzymes as potential 
therapeutic targets. To date, successful attempts at developing inhibitors for 
epigenetic targets have been made, with the histone deacetylases (HDAC) family 
being the most prominent example. Vorinostat and romidepsin are HDAC 
inhibitors that are already FDA approved for blood cancers, and many others are 
currently under clinical trials (Yu et al., 2015). Unfortunately, the clinical success 
of HDAC inhibitors in solid tumors has been very limited. Thus, it is imperative to 
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explore other critical epigenetic enzyme families like PRMTs by developing HTS 
screens and identifying potential inhibitors of clinical significance.  
 
Various assays for HTS that have been used in recent times were 
considered to screen for PRMT family member inhibitors. Among the current 
available technologies, AlphaLISA proved to be an excellent choice for this 
purpose for various reasons. For instance, in the case of radiometric assays, the 
cost and danger associated with its usage and the generation of radioactive 
waste are a huge deterrent. Enzyme-based assays like ELISA have been quite 
popular for screening in the past. However, with these assays, the scaling-up 
approach can prove to be quite expensive and cumbersome. As the HTS field 
grows, there is a dire need to develop economical and scalable approaches to 
screen for active compounds against potential targets. AlphaLISA is a viable 
option because it provides a straightforward protocol for assay development, and 
its robustness, sensitivity, cost-effectiveness, and ease of use makes it an 
attractive screening tool. We conducted extensive troubleshooting and adapted 
all the loading volumes and concentrations to be compatible with a robotic 
system. A big limitation of the non-robotic approach is the cumbersome and 
expensive nature of the study, with addition of 10,000 compounds and reagents 
involved as part of the screening protocol. The ease of automation provided by 
our technique will help to drive high scale screening studies. Additionally, the 
robotic system allowed for higher accuracy with its state-of-the-art pipetting 
system as well as cost efficiency as it enables use of very low volumes of 
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reagents. If using the appropriate biotinylated substrate, methyl donor, 
epigenetic-tag specific Acceptor beads, and Streptavidin-coated Donor beads, 
this assay can be customized for other epigenetic targets as well. 
 
We employed a multi-step approach to identify top hits from small 
compound libraries with PRMT5 as our target. PR5-LL-CM01 was identified from 
the first screen and has already been discussed in the previous section. We 
conducted a 2nd HTS with compound libraries containing natural products and 
bioactives to identify even more inhibitors of PRMT5. Before running the second 
HTS, we tested its robustness using the reliable Z’ test, which was determined to 
be 0.7 (Figure 46). Upon completion of the screen of libraries containing natural 
products and biologically active compounds, we then sorted through the top hits. 
Our results indicated that P1608K04 and P1618J22 are the most effective 
PRMT5 inhibitors from our 2nd screen. Both compounds demonstrated 
considerable efficacy in concentration-dependent AlphaLISA assays (Figure 49), 
and in MTT assays in PDAC and CRC cells (Figure 50), respectively. We also 
confirmed the significant inhibitory effect of P1608K04 and P1618J22 on PRMT5-
mediated NF-kB methylation, activation, and its downstream target gene 
expression (Figures 51-53). Overall, our findings support the activity of these 
inhibitors against PRMT5.  
 
To understand how P1608K04 and P1618J22 may bind to PRMT5, we 
delved deeper into the mechanism of the inhibitor-enzyme interaction using 
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structural docking analyses, similar to PR5-LL-CM01. As shown in Figures 54A 
and B, we identified specific residues in the binding interaction between these 
two compounds and PRMT5. This analysis suggested that both inhibitors can 
potentially inhibit PRMT5 through certain similar but also varied mechanisms. For 
instance, both seem to bind to residues that intersect with the SAM binding site in 
the Apo states, suggesting that one possible way these inhibitors work is by 
interfering with SAM binding to its consensus site on PRMT5 structure. Ligand 
affinity map analysis (Figures 55A) suggests that both P1608K04 and P1618J22 
interact with two key residues (E444 and F327) that are unique to the PRMT5 
structure, also alluding to their specificity. As mentioned previously, both these 
residues play a crucial role in the PRMT5 methyltransferase activity (Schapira 
2014). Both P1608K04 and P168J22 could contribute to PRMT5 inhibition via the 
interaction with these two key residues. This binding poses of P1608K04 and 
P168J22 are also different from that of EPZ015666, suggesting that there is a 
distinction between our compounds and EPZ015666, and could possibly 
contribute to the different efficacies in inhibiting PRMT5 (Figures 54A-D). In the 
future, mutating some of these residues can help us locate critical sites on 
PRMT5 for the inhibitor-enzyme interactions and elucidate the mechanism of 
action of P1608K04 and P1618J22 for PRMT5 inhibition. Furthermore, several 
unique residues to each type of interaction such as E444 and F327 in the ligand 
affinity maps (Figures 55A and B) can be further pursued and analyzed in detail. 
Additionally, it would be of great interest to employ SAR analyses to design 
derivatives of the top hits. This would assist in maximizing the efficacy of these 
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compounds by reducing the therapeutic dosages needed to obtain significant 
anti-tumor efficacy. From a broader perspective, epigenetic enzymes are proving 
to be increasingly critical in a wide variety of diseases, and the approach 
described here can accelerate the development of important tools required for 
this purpose. 
 
In summary, we have identified the significant role of PRMT5 as a 
promoter of the various hallmarks of cancer in PDAC and CRC, as well as 
highlighted its potential to be exploited as an important therapeutic target (Figure 
56). Overall, the discovery of PR5-LL-CM01 may lead to promising new PDAC 
and CRC therapies and will help to better understand the workings behind PDAC 
and CRC. In the long run, we will move toward clinical trials with the few best-
characterized PR5-LL-CM01 derivatives with the ultimate goal of improving 
PDAC and CRC patient survivorship and treatment. 
 
6.2 Key Points for Consideration   
In this study, we highlighted a novel mechanism by which PRMT5 
overexpression could contribute to its tumor-promoting activity by affecting cell 
proliferation, migration, and anchorage independent growth of cancer cells, 
possibly via mediating NF-kB activation and could be therapeutically targeted by 
using PRMT5- selective inhibitors. We did not encounter any major obstacles 
while performing the work described in this thesis. However, I would like to 
describe some potential limitations associated with the experiments and the 
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results presented here. We generated stable overexpression and knockdown cell 
lines for PRMT5 expression in PANC1 and HT29 cells. We used a common 
vector control for both these cell lines but did not include scramble controls 
specifically for the shPRMT5 cell line for the phenotypic assays discussed in 
Chapter 3. The reason was because we cloned the PRMT5 gene into a lentiviral 
vector. It is a similar lentiviral vector as the shRNAs constructs. So predictably, 
the cells derived from the control vector and the shScramble construct shall be 
very similar. However, later on, I still generated shscramble cell lines and 
compared PRMT5 expression to vector control cell lines used in our experiment 
and confirmed the comparable PRMT5 expression between the two different 
control cell lines (Figure 57). Thus, we would anticipate no differences in the 
phenotype if we would have included the shscramble control in our studies from 
the vector control. In the future, the shscramble control will be included alongside 
any experiments that include the shPRMT5 cell line as an appropriate control 
though both control vectors are similar lentiviral vectors with same puromycin 
selection marker.  
 
Furthermore, the AlphaLISA assay is a powerful tool to screen for small 
molecule inhibitors of the desired target. Indeed, we were able to successfully 
identify potent inhibitors of PRMT5 activity using this technique. One limitation of 
this technique is the specific Acceptor beads that contain the antibody tag 




Figure 57. Comparison of PRMT5 Expression in Shscramble versus Ctrl 
Cell Lines 
Western blot, confirming comparable PRMT5 overexpression in shscramble cell 
lines as compared to the plv-vector control (Ctrl) cell line in (left) PANC1 and 





beads and have a wide repository of beads available that can detect almost all 
acetylation and arginine-based histone modifications. However, beyond these 
substrates, their catalog is limited. Thus, if one is interested to use the AlphaLISA 
assay with substrates not in the repository, it might be difficult to obtain the 
reagents required for the assay. An alternative is to work with PerkinElmer to 
design customized Acceptor beads that work with one’s time and budget 
constraints.  
 
Lastly, in this study, we used NSG mice, a widely used immunodeficient 
strain available as they lack mature T cells, B cells, and NK cells. 
Immunodeficient models reduce the chances of host rejection when human cell 
lines are implanted for growing tumors. These models have been widely applied 
in cancer research for mechanistic studies, early phase drug discovery, etc. but 
also have certain shortcomings (Lei et al., 2016). Since these mice do not have a 
functioning immune system, they do not replicate the human microenvironment 
where the immune system plays a key role in tumor dynamics. Additionally, mice 
and humans could have different isoforms of the same protein that may react to 
the drugs differently. Thus, there can be chances of the treatment regimen not 
being successful when tested in humans. To overcome this hurdle, 
immunocompetent models such as chemically induced, or genetically engineered 
models can be used in our studies before we move into the clinical trial phase, as 
these provide more accurate representation of the immune microenvironment 
compared to immunocompromised mice.  
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6.3 Future Directions 
The exciting work presented in this study highlights the critical role of 
PRMT5 in promoting the various hallmarks of cancer as well as NF-kB activation 
(Chapter 3) and presents a promising case for the potential of PRMT5 as a 
therapeutic target in PDAC and CRC (Chapters 4 and 5). It also opens up a 
plethora of exciting opportunities for future studies in this field.  
 
Building upon this exciting work, our immediate future plan would be to 
generate more efficacious derivatives of PR5-LL-CM01 with the ultimate goal of 
moving this discovery to clinical applications. We will do a more in-depth SAR 
analysis to identify compounds that can be even more efficacious than the 
parental compound.  In terms of how PR5-LL-CM01 inhibits PRMT5, one line of 
research to pursue would be to further verify the in silico model with purified 
PRMT5 crystal for the structure analysis. Specific residues that are potentially 
involved in the compound target interaction can be mutated to test if it would 
affect the binding kinetics. This will help to understand the exact interactions 
between the compound and target. In addition, structural docking analysis could 
be carried out for its promising derivative PPA-1, to compare what are the 
similarities and differences between the parental compound and PPA-1. This in-




Furthermore, in order to establish the selectivity of PR5-LL-CM01 are at 
least partly via reducing NF-kB activation, we can probe the mouse tissue from 
tumor efficacy studies to test the hypothesis that PR5-LL-CM01 treatment would 
lead to a decrease in p65 methylation in the PDAC and CRC tissue, as PR5-LL-
CM01 would inhibit PRMT5-mediated activation of NF-kB. qPCR analyses can 
also be conducted on this tissue to check if decrease in activation of NF-kB also 
leads to a decrease in downstream NF-kB target gene expression in the tissue. 
In addition, we used the Sepharose beads approach as described in Chapter 4 
to test binding of PR5-LL-CM01 directly to PRMT5. This proved to be 
unsuccessful as the beads did not conjugate with our inhibitor. This perhaps was 
because PR5-LL-CM01 does not have the required primary amine crucial for 
conjugation step. Furthermore, we also attempted to use CETSA assays (as 
described in Chapter 4) involving Western blotting for this purpose, but only to 
limited success as the variation in quantification for the different blots was quite 
high. Though the result had promising trend, it did not have statistically significant 
difference. As for in vitro binding studies, we attempted the ITC (described in 
Chapter 4) experiment to determine binding. Briefly, this method allows us to 
measure thermodynamic parameters upon binding of PR5-LL-CM01 and PRMT5 
in solution. However, this approach was proved to be unfeasible for our purpose. 
This is mainly because very high concentrations of enzyme of protein are 
required for the experiment. In the future, we are planning to work with Dr. Lan 
Chen (currently at Purdue Chemical Genomics Facility) to fluorescently label 
PRMT5 using the Monolith NT™ Protein Labeling Kit. Furthermore, we plan to 
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use microscale thermophoresis approach which is capable of analyzing 
interactions of proteins/small molecules in pure form or in biological samples 
such as cell lysates (Wienken et al., 2010). Thermophoresis is related to the 
directed motion of molecules that is directed by temperature gradients. Briefly, 
the assay principle is that binding interaction of a fluorescently labeled protein 
with its partner leads to changes in distribution of infrared laser light. These 
changes can be measured over time until the reaction reaches equilibrium and 
can be quantified to get an idea of the binding parameters. A major advantage of 
this method is that it can be used to conduct both binding studies using protein in 
pure form as well as present in cell lysates. Overall, this approach could help in 
demonstrating the direct binding interaction between PR5-LL-CM01 and PRMT5 
in the future. 
 
Furthermore, cancer is a heterogeneous disease and a single targeted 
therapeutic agent could be overly optimistic. Combination studies have shown 
limited success in the clinic. In the same way, PR5-LL-CM01 could be combined 
with current chemotherapeutic drugs (for instance, the FOLFIRINOX or FOLFOX 
regimen mentioned in the Introduction section which is most widely used 
regimen) for PDAC and CRC to test if this would be an effective way as 
compared to the therapeutic drugs alone in reducing the disease phenotype. 
Additionally, thorough safety studies will need to be conducted using larger 
samples sizes of mice as well as incorporating the female mice in the studies as 
well, in order to determine the optimal dosing regimen for Phase 1 trials. Going 
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forward, such studies would provide a more realistic approach if this compound 
makes it way from the bench to the bedside. 
 
Along with establishing a better understanding of the mechanism of action 
of PR5-LL-CM01 and its link to NF-kB as a substrate for PRMT5, it is also 
important to consider that PRMT5 has other substrates besides NF-kB. It would 
be interesting to check if the inhibitory properties of PR5-LL-CM01 extend 
beyond PRMT5 and NF-kB and if they have anti-tumor implications. Some 
PRMT5 substrates are important in the context of cancer, including p53 and 
EGFR and changes in symmetric dimethylation levels at these sites in the 
presence of PR5-LL-CM01 can be detected. However, it is important to keep in 
mind that these site-specific modifications could be specific to the tissue/cell type 
they were discovered in and not significant in the models described in this study. 
If shown to be important in the context of PDAC and/or CRC, more detailed 
studies can be conducted in the future to check if multi-substrate targeting works 
in concert with reducing the tumor. 
 
Lastly, the therapeutic role of PRMT5 can be extended beyond PDAC and 
CRC to other cancers. NF-kB is constitutively activated in a variety of cancers 
and PRMT5 is overexpressed in different cancers as well. It would be of 
particular interest to test the efficacy of PRMT5 inhibition in slowing down cancer 
progression. The ultimate goal is to translate the findings from the bench and 
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Appendix A. Permissions 
Below is the information pertaining to permission from journals to use my first-
















Gene Name  Primer Lab Record Primer Sequence Used 
GAPDH 1 F326 CCATCACCATCTTCCAGGAGCG 
2 R468 AGAGATGATGACCCTTTTGGC 
IL8 3 F139 TCCTGATTTCTGCAGCTCTGT 
4 R245 AAATTTGGGGTGGAAAGGTT 
IL1a 5 F218 TGGCCCAGGCAGTCAGA 
6 R286 GGTTTGCTACAACATGGGCTACA 
TNFa 7 F412 GACGCCCTCAATCAAAGTATAATTC 
8 R500 TCAAATTTCACTGCTTCATCCAGAT 
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Appendix C. Synthesis Rationale for 1st Set of Derivatives 
Synthesis of derivatives was conducted by Dr. Lifan Zeng from the IU Chemical 
Genomics Core as described by him below.  
 
1. Synthesis of PM-1 
 
 
The mixture of the compound 1 (55.8mg, 0.2mmol), morpholine (17.42mg, 
18.9mg, 0.2mmol), and K2CO3 (55.2mg, 0.4mmol) in MeCN (9 mL) was stirred at 
30oC for 16h, The reaction was monitored by TLC, after completion of the 
reaction, the reaction mixture was filtered and concentrated in vacuum to obtain 
crude product. The crude product was purified through silica gel column 
chromatography using DCM and DCM/EtOAc（20/1-5/1） to afford compound 
PM-1 as an off-white solid (65 mg, Yield 42%). 1H NMR (400 MHz, CDCl3) δ 8.04 
(s, 1H), 7.92 (d, J=8.5, 2H), 7.30 (d, J=8.3, 2H), 4.01 – 3.96 (m, 4H), 3.88 – 3.85 
(m, 4H), 2.40 (s, 3H). 
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2. Synthesis of PPA-1 
Not included as part of a pending patent application. 
 
3. Synthesis of PTF-1 
 
 
The mixture of the compound 1 (111.6mg, 0.4mmol) and K2CO3(110.4 mg, 0.8 
mmol) in MeCN (16mL). To the reaction mixture was added 
tetrahydrofurfurylamine (43.2 mg, 50.8mg, 0.4mmol) and then stirred at 30oC for 
16 h, The reaction was monitored by TLC, after completion of the reaction, the 
reaction mixture was filtered and concentrated in vacuum to obtain crude 
product. The crude product was purified through silica gel column 
chromatography using DCM and DCM/EtOAc (4/1-2/1) to afford compound PTF-




4. Synthesis of PAM-1 
 
To the mixture of the compound 1 (111.6 mg, 0.4 mmol) and K2CO3(110.4 mg, 
0.8 mmol) in MeCN(16 mL) was added 4-(2-Aminoethyl)morpholine (52 mg,54.3 
mg, 0.4 mmol) and then stirred at 30 oC for 16 h, The reaction was monitored by 
TLC, after completion of the reaction, the reaction mixture was filtered and 
concentrated in vacuo to obtain crude. The crude product was purified through 
silica gel column chromatography using DCM and DCM/EtOAc（1/1） to afford 




5. Synthesis of BAM-1 
 
To the mixture of compound BBL (120.0 mg, 0.4 mmol) and K2CO3(110.4 mg, 0.8 
mmol) in MeCN(16 mL) was added 4-(2-Aminoethyl)morpholine (52 mg, 55.3 mg, 
0.4 mmol) and then stirred at 30 oC for 16 h, The reaction was monitored by TLC
（DCM/MeOH=12/1）, after completion of the reaction, the reaction mixture was 
filtered and concentrated in vacuo to obtain crude. The crude product was 
purified through silica gel column chromatography using EtOAc and 




7. Synthesis of BPM-1 
 
 
To the mixture of the compound BBL (120 mg, 0.4 mmol), morpholine (34.84 mg, 
37.4 mg, 0.4 mmol), and K2CO3(110.4 mg, 0.8 mmol, 111.3 mg) in MeCN(15 mL) 
was stirred at 30 oC for 16 h, The reaction was monitored by TLC, after 
completion of the reaction, the reaction mixture was filtered and concentrated in 
vacuo to obtain crude. The crude product was purified through silica gel column 
chromatography using DCM/Hexane (1/1) and DCM to afford compound BPM-1 




8. Synthesis of BTF-1 
 
 
To the mixture of the compound BBL (120.6 mg, 0.4 mmol) and K2CO3 (110.4 
mg, 0.8 mmol, 115 mg) in MeCN(16 mL) was added tetrahydrofurfurylamine 
(43.2 mg, 49.1 mg, 0.4 mmol) and then stirred at 30 oC for 16 h, The reaction 
was monitored by TLC (DCM/EtOAc=4/1), after completion of the reaction, the 
reaction mixture was filtered and concentrated in vacuum to obtain crude 
product. The crude product was purified through silica gel column 
chromatography using DCM and DCM/EtOAc（4/1） to afford compound BTF-1 




10. Synthesis of BAP-1 
 
The mixture of the compound BBL (120.6 mg, 0.4 mmol, 122 mg) and K2CO3 
(110.4 mg, 0.8 mmol, 116.4 mg) in MeCN(16 mL). To the reaction mixture was 
added 1-(2-Aminoethyl)pyrrolidine (45.6 mg, 50 mg, 0.4 mmol) and then stirred at 
30 oC for 16 h, The reaction was monitored by TLC（DCM/MeOH=8/1）, after 
completion of the reaction, the reaction mixture was filtered and concentrated in 
vacuo to obtain crude. The crude product was purified through silica gel column 
chromatography using EtOAc and EtOAc / MeOH（20/1-10/1） to afford 
compound BAP-1 as an off-white solid (46 mg, Yield 27.8%). 1H NMR (400 MHz, 
CDCl3) δ = 8.48 (s, 1H), 8.12 (d, J=8.9, 2H), 7.46 (d, J=8.9, 2H), 4.02 (s, 2H), 






11. Synthesis of PAMHP-2-5 
 
Not included as the synthesis involves PPA-1 which is confidential as part of 
pending patent application. 
 




yl)ethane-1,2-diamine. The mixture of the compound PM-1 (30.1 mg, 0.1 mmol) 
and triethylamine (0.5 mL) in N,N-Dimethylethylenediamine (3 mL)  was stirred at 
30 oC for 3 h, and then warmed to 120 oC and stirred for 16 h. The reaction was 
monitored by TLC (DCM/Hexane/triethylamine =6/3/0.5), after completion of the 
reaction, the reaction mixture was filtered and concentrated in vacuum to obtain 
crude product, which was purified through silica gel column chromatography 
using (DCM/ Hexane/triethylamine =6/6/0.5) to afford compound PAMPH-1(6.2 
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mg) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ = 8.06 (d, J=7.6, 2H), 
7.88 (s, 1H), 7.25 (s, 2H), 3.93 – 3.88 (m, 4H), 3.86 – 3.82 (m, 4H), 3.68 – 3.52 
(m, 4H), 2.39 (s, 3H), 2.30 (s, 6H). ESI-MS: (M + H)+ calculated  for C20H27N7O, 
381.47; found,382.23.  
 




N2,N2-dimethylethane-1,2-diamine. The mixture of the compound BPM-1 (35 
mg, 0.1 mmol)and triethylamine (0.5 mL) in N,N-Dimethylethylenediamine (3 mL) 
was stirred at 30 oC for 3 h, and then warmed to 120 oC and stirred for 16 h. The 
reaction was monitored by TLC (DCM/Hexane /triethylamine =6/3/0.5), after 
completion of the reaction, the reaction mixture was filtered and concentrated in 
vacuum to obtain crude product, which was purified through silica gel column 
chromatography using (DCM/ Hexane/triethylamine =6/6/0.5) and (DCM/ 
Hexane/triethylamine =6/3/0.5) to afford compound PAMHP-6PM (10.0 mg) as 
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an off-white solid. 1H NMR (400 MHz, CDCl3) δ = 8.23 (d, J=8.6, 2H), 7.89 (s, 
1H), 7.42 (d, J=9.0, 2H), 3.93 – 3.87 (m, 4H), 3.86 – 3.82 (m, 4H), 3.69 – 3.62 
(m, 4H), 2.34 (s, 6H). ESI-MS: (M + H)+ calculated  for C19H24ClN7O, 401.89; 
found,402.18.  
 
14. Synthesis of PAMHP-8TF 
 
   
 
The mixture of the compound BTF-1 (36.4 mg, 0.1 mmol) and triethylamine (0.5 
mL) in N,N-Dimethylethylenediamine (3 mL) was stirred at 30 oC for 3 h, and then 
warmed to 120 oC and stirred for 16 h. The reaction was monitored by TLC 
(DCM/Hexane /triethylamine =6/3/0.5), after completion of the reaction, the 
reaction mixture was filtered and concentrated in vacuum to obtain crude 
product, which was purified through silica gel column chromatography using 
(DCM/ Hexane/triethylamine =6/3/0.5) to afford compound PAMHP-8TF (12.7 
mg) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ = 8.24 (d, J=8.7, 2H), 
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7.84 (s, 1H), 7.41 (d, J=9.0, 2H), 4.13 (d, J=7.2, 1H), 4.00 – 3.86 (m, 2H), 3.81 
(d, J=8.2, 1H), 3.67 – 3.54 (m, 4H), 2.64 (t, J=6.1, 2H), 2.36 (s, 6H), 1.97 (s, 
4H).ESI-MS: (M + H)+ calculated  for C20H26ClN7O, 415.92; found,416.2.  
 





pyrazolo[3,4-d]pyrimidine-4,6-diamine. The mixture of compound PTF-1 (34.1 
mg, 0.1 mmol), N,N-Dimethylethylenediamine (0.2 mL), and K2CO3(100 mg, 0.8 
mmol) in n-BuOH (12 mL) was stirred at 30 oC for 3 h, and then warmed to 130 
oC and stirred for 16 h. The reaction was monitored by TLC 
(EtOAc/DCM/MeOH=3/6/1), after completion of the reaction, the reaction mixture 
was filtered and concentrated in vacuo to obtain crude product, which was 
purified through silica gel column chromatography using DCM and DCM/EtOAc（
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1/1），and then preparative HPLC with gradient started at 20% MeCN in water, 
increase to 40% MeCN at 8 min and ended at 100% water after 11 min with 0.1% 
of TFA to afford compound PAMHP-3 (6.4 mg) as an off-white solid. 1H NMR 
(400 MHz, CDCl3) δ 9.40 (s, 1H), 8.10 (s, 1H), 7.77 (d, J = 8.0 Hz, 2H), 7.29 (d, J 
= 8.1 Hz, 2H), 4.28-4.21 (m, 1H), 3.97-3.87 (m, 3H), 3.84-3.68 (m, 3H), 3.30 (s, 
2H), 2.83 (s, 6H), 2.41 (s, 3H), 2.18-2.12 (m, 1H), 2.05-1.97 (m, 2H), 1.80-1.71 
(m, 1H). ESI-MS: (M + H)+ calculated  for C21H29N7O, 395.50; found,396.3. 
Purity: 98.4% (254nm). 
 





pyrazolo[3,4-d]pyrimidine-4,6-diamine. The mixture of the compound PAM-1 
(75 mg, 0.2 mmol) and triethylamine (0.5 mL) in N, N-Dimethylethylenediamine 
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(3 mL) was stirred at 30 oC for 3 h, and then warmed to 120 oC and stirred for 16 
h. The reaction was monitored by TLC (DCM/ triethylamine =8/0.5), after 
completion of the reaction, the reaction mixture was filtered and concentrated in 
vacuum to obtain crude product, which was purified through silica gel column 
chromatography using DCM/ triethylamine (8/0.5), and then the preparative 
HPLC gradient started at 20% MeCN in water, increase to 40% MeCN at 8 min 
and ended at 100% water after 11 min with 0.1% of TFA to afford compound 
PAMPH-5-5 (6.9 mg) as an off-white solid.1H NMR (400 MHz, CD3OD) δ 7.98 (s, 
1H), 7.79 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 3.96 (d, J = 5.8 Hz, 6H), 
3.78 (t, J = 5.4 Hz, 2H), 3.48 (t, J = 5.7 Hz, 4H), 3.39 – 3.32 (m, 4H), 2.81 (s, 6H), 
2.41 (s, 3H). ESI-MS: (M + H)+ calculated for C22H32N8O, 424.54; found,425.3. 
Purity: >98% (HPLC). 
 





1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine. The mixture of the compound BAP-
1 (37.7 mg, 0.1 mmol) and triethylamine (0.5 mL) in N,N-
Dimethylethylenediamine (3 mL) was stirred at 120 oC for 16 h. The reaction was 
monitored by TLC (DCM/ triethylamine =20/1), after completion of the reaction, 
the reaction mixture was filtered and concentrated in vacuum to obtain crude. 
The crude product was purified through silica gel column chromatography using 
DCM / petroleum ether/trimethylamine (100/10/5), DCM/triethylamine (20/1) and 
DCM / MeOH / triethylamine (200/15/109), and then the preparative HPLC 
gradient started at 20% MeCN in water, increase to 40% MeCN at 8 min and 
ended at 100% water after 11 min with 0.1% of TFA to afford compound PAMHP-
9 (6.6 mg) as an off-white solid. 1H NMR (400 MHz, CD3OD) δ 8.10 (d, J = 8.9 
Hz, 2H), 8.01 (s, 1H), 7.50 (d, J = 8.9 Hz, 2H), 3.92 (t, J = 5.6 Hz, 2H), 3.84 (t, J 
= 5.8 Hz, 4H), 3.51 (t, J = 5.7 Hz, 2H), 3.42 (t, J = 5.8 Hz, 2H), 3.17 (s, 2H), 2.90 
(s, 6H), 2.16 (s, 2H), 2.05 (s, 2H). ESI-MS: (M + H)+ calculated for C21H29ClN8, 




18. Synthetic of PAMHP-4 
 
 
The mixture of the compound PAP-1 (~55.1 mg, 56.8 mg, 0.15 mmol), N,N-
Dimethylethylenediamine (0.15 mL), and K2CO3(75 mg, 0.6 mmol, 79.8 mg) in n-
BuOH (15 mL) was stirred at 30 oC for 3 h, and then warmed to 130 oC and 





19. Synthesis of PAMHP-7 
 
The mixture of the compound BPA-1 (37.1 mg, 0.1 mmol) and triethylamine (0.5 
mL) in N,N-Dimethylethylenediamine (3 mL) was stirred at 120 oC for 16 h. The 
reaction was monitored by TLC (DCM/MeOH/triethylamine =10/1/0.5), after 
completion of the reaction, the reaction mixture was filtered and concentrated in 
vacuum to obtain crude product, which was purified through silica gel column 
chromatography using DCM and (DCM/MeOH/triethylamine =10/1/0.5) to afford 
compound PAMHP-7 (10 mg) as an off-white solid. Yield 10.5 mg, 32%. 1H NMR 
(400 MHz, CD3OD) δ 8.87 (s, 1H), 8.72 (s, 1H), 8.51 (s, 1H), 8.14 (d, J = 9.0 Hz, 
2H), 8.07 (s, 1H), 7.93 (s, 1H), 7.52 (d, J = 8.9 Hz, 2H), 4.93 (s, 2H), 3.80 (t, J = 
5.8 Hz, 2H), 3.38 (t, J = 6.5 Hz, 2H), 3.20 (s, 1H), 2.89 (s, 6H). ESI-MS: (M + H)+ 




20. Synthesis of PAMPH-10 
 
The mixture of the compound BAM-1 (39.3 mg, 0.1 mmol) and triethylamine (0.5 
mL) in N,N-Dimethylethylenediamine (3 mL)  was stirred at 30 oC for 3 h, and 
then warmed to 120 oC and stirred for 16 h. The reaction was monitored by TLC 
DCM /triethylamine (8/0.5), after completion of the reaction, the reaction mixture 
was filtered and concentrated in vacuum to obtain crude product, which was 
purified through silica gel column chromatography using DCM /triethylamine 
(8/0.5) to afford compound PAMHP-10 as an off-white solid. Yield 25 mg, 57%. 
1H NMR (400 MHz, CD3OD) δ 8.87 (s, 1H), 8.72 (s, 1H), 8.51 (s, 1H), 8.14 (d, J = 
9.0 Hz, 2H), 8.07 (s, 1H), 7.93 (s, 1H), 7.52 (d, J = 8.9 Hz, 2H), 4.93 (s, 2H), 3.80 
(t, J = 5.8 Hz, 2H), 3.38 (t, J = 6.5 Hz, 2H), 3.20 (s, 1H), 2.89 (s, 6H). ESI-MS: (M 
+ H)+ calculated  for C21H29ClN8O, 444.96; found,445.2.  
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Appendix D. Conditions Optimized for Detection of PR5-LL-CM01 using LC-
MS 
This work was conducted by Dr. David Jones and colleagues at the IU Clinical 
Pharmacology Analytical Core.  
HPLC conditions 
Column:  Agilent Zorbax 300SB-C8 150 x 4.6 mm 5 micron 
Mobile Phase: acetonitrile: 0.1% formic acid  
  A: 20:80; v/v 
  B: 80:20; v/v 
Flow:  600µL/min  
Time (min.) %A %B 
0 100 0 
2 0 100 
7 0 100 
7.1 100 0 
10 100 0 
Mass spectrometry conditions 
Positive mode 
Compound Q1 Q3 Time (msec) DP EP CE CXP 
PR5-LL-CM01 402.1 357.3 100 50 10 30 15 
Acetaminophen (IS) 152.0 109.3 100 80 12 20 10 
 
Temperature: 600     CAD: medium    
Curtain Gas: 15     IS: 3000  
Source Gas 1: 50     Source Gas 2: 50   
Resolution: Unit for Q1 and Q3 
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